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Full abstract  
 
Solid tumors are complex biological structures which are composed of cellular and 
matrix components, everything being perfused by blood vessels. During tumor 
development, modifications of both biochemical and mechanical parameters are 
observed and can feedback on one another. Cancer cells constantly interact with their 
mechanical environment and the whole tissue is mostly confined by its surrounding. 
Compressive mechanical stress develops in part from cell proliferation and could 
eventually result in the clamping of blood vessels leading to increased interstitial 
fluid pressure (hydrostatic pressure). The consequent hypoperfusion poses important 
obstacles to drug delivery and nanomedicines. In fact, the tortuous tumor 
microvasculature has blood velocities up to one order of magnitude lower compared 
to healthy capillary networks. Moreover, the fast angiogenesis during tumor 
progression leads to high vascular density in solid tumors, large gaps exist between 
endothelial cells in tumor blood vessels, and tumor tissues show selective 
extravasation and retention of macromolecular drugs (Enhanced Permeation 
Retention – EPR – effect). These effects have served as a basis for the development 
of drug delivery systems which are aimed at enhancing tumor tissue targeting and 
drug therapeutic effectiveness. Over the last 15 years, a plethora of materials and 
different formulations have been proposed for the realization of nanomedicines. Yet, 
drug-loading efficiency, sequestration by phagocytic cells, and tumor accumulation 
of nanoparticle-loaded agents - nanomedicines - are sub-optimal. 
Starting from these considerations, during my PhD, I studied two complementary 
approaches: in the first two years my work was focused on implementing the 
characteristics of Discoidal Polymeric Nanoconstructs designed with controlled 
geometries and mechanical properties. In the last year, I investigated the role of 
mechanical stress on chemotherapeutic efficacy. 
More precisely, this work first reviews the use of deformable discoidal 
nanoconstructs (DPNs) as a novel delivery strategy for therapeutic and imaging 
agents. Inspired by blood cell behavior, these nanoconstructs are designed to 
efficiently navigate the circulatory system, minimize sequestration by phagocytic 
cells, and recognize the tortuous angiogenic microvasculature of neoplastic masses. 
In this work, the synthesis, drug loading and release, and physico-chemical 
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characterization of DPNs were enhanced with particular emphasis on the ability to 
independently control size, shape, surface properties, and mechanical stiffness. Two 
different loading strategies were tested, namely the straightforward “direct loading” 
and the “absorbance loading”. In the former case, the agent was directly mixed with 
the polymeric paste to realize DPNs whereas, in the latter case, DPNs were first 
lyophilized and then rehydrated upon exposure to a concentrated aqueous solution of 
the agent. Under these two loading conditions, the encapsulation efficiencies and 
release profiles of three different molecules and their corresponding prodrugs were 
systematically assessed (1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine lipid 
chains or 1 kDa PEG chains were directly conjugated with Cy5.5 or methotrexate 
and Doxorubicin). Moderately hydrophobic compounds with low molecular weight 
showed encapsulation efficiencies of 80%, with absorption loading (direct loading 
has efficiencies around 1%). The DOX-DPN showed on triple negative breast cancer 
cells a toxicity comparable to free DOX. Preliminary in vivo preliminary studies 
conducted with directly loaded Cy5-DPN demonstrated a fairly solid integration of 
the imaging compound with the polymer matrix of the particles. 
The second part of the work dissect what happens to free drugs or to drugs carried by 
nanovectors once they reach the tumor site. As we mention above, the elevated 
mechanical stress derived from tumor progression could result in blood vessels 
clamping with consequent reduction of drug efficacy. It is quite obvious to imagine 
that if the drug fails to reach the tumor it cannot act on it. Indeed, mechanical stress 
within the tumor site is present from the early stages of the disease. Our goal was to 
understand what happens when mechanical stress is not yet so large enough to fully 
collapse the blood vessels.  Are there mechanical alterations that can affect the 
efficacy of a chemotherapeutic? We studied how mechanical perturbations of the 
tumor microenvironment could contribute to the mechanical-form of Gemcitabine 
drug resistance. 
Specifically, we developed a new in vitro strategy to mimic the mechanical 
compression stress induced by the stroma during tumor progression. We embedded 
pancreatic tumor spheroids into agarose polymeric matrix in order to demonstrate the 
effect of mechanical compressive stress on tumor proliferation. Then, we validated 
our results with other types of mechanical stresses. Finally, we investigated the 
therapeutic efficacy of a proliferation-based chemotherapy: Gemcitabine. 
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Collectively, having the physical cues of cancer in mind, it can be important to cross-



























In these three years I had the opportunity to know two different multidisciplinary 
environments, I adapted myself to two different scientific contexts and I learned to 
look at things from more perspectives. 
I spent my first 2 years of my PhD in the Laboratory of Nanotechnology for 
Precision Medicine at the Italian Institute of Technology (IIT) in Genova – Italy, 
under the supervision of  Dr Paolo Decuzzi. 
At the IIT we reviewed the use of deformable discoidal nanoconstructs (DPNs) as a 
novel delivery strategy for tumor therapy and imaging. We optimized the synthesis 
procedure, drug loading and release as well as the physico-chemical characterization 
of DPNs. Moreover, two different loading strategies were tested and the 
encapsulation efficiencies and release profiles of three different molecules and their 
corresponding prodrugs were systematically assessed. 
In the third year of my PhD I went abroad in Toulouse (France) in the MILE group at 
the LAAS-CNRS under the supervision of Dr. Morgan Delarue. For six months of 
that period, I mainly worked at CRCT (Centre de Recherches en Cancérologie de 
Toulouse) in the Julie Guillermet’s research group (Morgan Delarue’s collaborator) 
to acquire skills on biological techniques and pancreatic cancer. 
In the MILE team we investigated the effect of a drug from another perspective: 
considering that the drug entered the tumor, we worked on how mechanical 
perturbations of the tumor microenvironment may contribute to modulating the 
efficacy of a drug.  
Each project require specific introduction and chapters, so I decided to write my 
work accordingly. Each chapter has a dedicated introduction, methods, results, 
conclusion and discussion. I finish my thesis by a global discussion on nanomedicine 
and mechanics.  
Specifically, the manuscript is organized in five main chapters which read as follows. 
Chapter 1 Introduction: brief global introduction of the two main thesis topics. 
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Chapter 2 Tune and strengthen of DPNs features for theranostic applications: 
context composed of a global view of the existing nanomedicine systems, main 
obstacles of their development (physiology of the tumor, immune response and poor 
efficiency of drug loading); focus of the work, presentation and evaluation of the 
developed methods and results, and finally main conclusions.  
Chapter 3 Mechanical control of chemotherapeutic drug efficacy: context 
composed of the role of mechanical stress during the cancer progression, 
mechanical-forms of drug resistance, Gemcitabine chemotherapeutic mechanism of 
action and pancreatic cancer cells as a model of this study; focus of the work, 
presentation and evaluation of the developed methods and results, and finally main 
conclusions.  
Chapter 4 Conclusion and prospective: global conclusion and discussion on the 
two main topics, connecting the dots and describing the next challenges, and how my 
work rationalize some of these challenges. 
Valorization: brief description of the two main objectives and emphasis on the main 
activities and publications disseminated during this PhD work. 
Appendix: a. Nanotechnology tools (brief description of the main nanotechnology 
instruments used for the nanofabrication and particles characterization, I reported 
also the references of the books where they come from and on which there are the 
full descriptions); b. A mathematical model perfectly predicts the effect of 
compressive stress on drug efficacy (full mathematical specifications of the model 
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1. Chapter: Introduction 
Solid tumors consist of different structural components in addition to tumor cells, such as 
blood and lymphatic vessels, the extracellular matrix (ECM) with its more common 
constituents that are collagen, hyaluronan and stromal cells. The presence of these 
components in a solid tumor can vary depending on the type, organ of origin and stage of 
growth and can participate in mechanical stress generation inside and around the tumor. 
Considering the fact that tumor progression is described by the development of tumor and/or 
stromal mass at the expense of the surrounding host tissue, the development of a tumor is 
associated with the generation and accumulation of mechanical stress. In this sense, solid 
tumors carry an interesting and complex mechanical system involving both solid and fluid 
mechanics in which the stresses arising from the solid phase of a tumor determine, largely, 
both fluid stresses and cancer progression (1) (2).  Solid stresses can affect the physiology of 
tumor cells either directly by compressing them, or indirectly by compressing blood and 
lymphatic vessels. On the one hand, compressive mechanical stress partly develops from cell 
proliferation in a confined environment, and can modulate cell division and migration and 
potentially induce cell death (3) (4) (5) (6) (7). Futhermore, the compression of the blood 
vessels causes hypoperfusion and dysfunction of the lymphatic vessels. Hypoperfusion and 
interstitial hypertension pose important obstacles to drug delivery and may exclude large 
intratumor areas from chemotherapeutic agents coming from the blood, which could lead to 
reduced efficacy of chemotherapy and nanomedicine (8) (9).  
Despite the multiple origins of solid stress involved in tumors and their pleiotropic role in 
tumor progression and treatment, few works have been dedicated to the area of cancer 
biomechanics and compressive solid stress.   
During tumor development, modifications of blood vessels permeation and blood velocity 
occur. Angiogenesis leads to high vascular density in solid tumors, large gaps exist between 
endothelial cells in tumor blood vessels, and tumor tissues show selective extravasation and 
retention of macromolecular drugs (Enhanced Permeation Retention – EPR – effect) (10). 
More importantly, the tortuous tumor microvasculature has significantly different biophysical 
features as compared to healthy capillary networks. The mean blood velocities in tumors are 
up to one order of magnitude lower because of the overall higher hydraulic resistance and 
lower perfusion, as compared to normal vascular networks (11). These effects serve as a basis 
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for development of new types of nanomedicines. Over the last 15 years, a plethora of 
materials and different formulations have been proposed for the realization of nanomedicines. 
Yet, drug-loading efficiency, sequestration by phagocytic cells, and tumor accumulation of 
nanoparticle-loaded agents - nanomedicines - are sub-optimal. (12) 
Starting from these considerations, two complementary approaches to study these issues were 
tried: first, an attempt was made to implement the characteristics of controlled release 
specialized nanovectors (Chapter 2), then we investigated the role of mechanical stress on 
therapeutic efficacy (Chapter 3). 
In particular in the first work, a top-down hybrid fabrication strategy, combining nanoscale 
lithographic techniques, wet etching, and polymer chemistry, was developed to tailor the size, 
shape, surface properties, and mechanical stiffness of Discoidal Polymeric Nanoconstructs. 
Atomic force microscopy was conveniently used for testing the mechanical properties of these 
Nanoconstructs. Moreover, was enhanced the encapsulation and stability of payloads of 
DPNs: was identified a new loading strategy for achieving encapsulation efficiencies well 
above 80%. The geometrical properties of all DPN configurations were plenty characterized 
using transmission electron microscopy, multisizer coulter counting, and dynamic light 
scattering. In addition, Miguel Ferreira and other colleagues did a systematic analysis of the 
loading and release for a variety of imaging and therapeutic agents loaded into DPNs (1,2-
Distearoyl-sn-glycero-3-phosphorylethanolamine lipid chains or 1 kDa PEG chains were 
directly conjugated with Cy5.5 or methotrexate and doxorubicin). 
In the second part we investigated how mechanical stresses modulate the response to 
biochemical signaling. Several recent works suggest that mechanical stresses alter chemical 
signaling from the microenvironment, which can play a role in tumor progression. In this 
context however, the precise role of the microenvironment and its interactions with the tumor 
are poorly understood (13). Recent evidences notably suggest that increased rigidity of the 
microenvironment is linked to resistance of solid tumors to chemotherapy. We investigated 
the impact of mechanical stress, in particular compressive, in the efficacy of drug treatment. 
We demonstrated a reduction in proliferation of compressed pancreatic cancer spheroids then, 






2. Chapter: Tune and strengthen of DPNs features for theranostic 
applications. 
 
2.1. Context  
 
2.1.1. Nanomedicine 
Nanomedicine is the application of nanotechnology to medicine (14) (15) (16). Nanomedicine 
derive from the merging of different knowledges coming from chemistry, biology, physics, 
mathematics, and engineering (17). However, biological, physical, chemical, mechanical, and 
optical properties at the nanoscale level differ from those of the larger, “bulk”, counterparts.  
The most important concept in this field is the possibility to design multifunctional 
nanoparticles (NPs) that can provide numerous benefits. In particular, compared to 
conventional medicines, NPs can improve efficacy, bioavailability, targeting ability, and 
safety of systemically administered drugs (14) (18) (19) (20).  
The physical characteristics of NPs can differ in many ways (21). Among the key parameters, 
there are: 
- Size: NPs have at least one dimension in the range of 1 to 100 nm, although they can 
also be micrometer-sized particles. In this way they have novel structural, optical, and 
electronic properties. They also have improved solubility and increased bioavailability and 
circulation time; 
- Shape: NPs can be spheres, discs, hemispheres, cylinders, cones, tubes, and wires. In 
this way, different physical and steric interactions, loading capacity, and transport capabilities 
can be modulated; 
- Surface area: as particles size decreases, the ratio between volume and exposed area 
increases significantly. An increase in surface area means that a greater portion of atoms are 
located on the particles surface relative to the core. This makes NPs more reactive and more 
prone to be conjugated with electrostatic charges or biomolecules selected for targeting or 
other purposes; 
- Permeability: NPs small size can facilitate the crossing of biological barriers that are 
normally not accessible. For example, NPs can transport anti-cancer drugs into tumors 
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according to the Enhanced Permeation and Retention (EPR) effect, through which drug 
delivery systems smaller than 200 nm should target passively tumors (22);  or they can cross 
the blood-brain barrier through the use of different uptake mechanisms. 
One of the most interesting capability in nanomedicine is the functionalization of NPs by 
altering NPs properties through chemical or physical modifications applied to achieve a 
specific effect. Various approaches to functionalize NPs include: 
- Targeting: NPs can be actively targeted using cell-specific ligands, magnetic 
localization, and/or size based selectivity (23) (24). The targeting property can enhance the 
efficacy of NP drug-delivery systems while significantly reducing toxicity (22);  
- Surface Conjugation: the NP surface can be conjugated to a lot of biomolecules for 
different purposes. Some candidates are fluorescent dyes for imaging (25), agents for genetic 
therapy such as small inhibitory RNA (siRNA) (26), targeting molecules that bind to highly 
expressed tumor cell receptors to facilitate the transport of imaging contrast agents, which aid 
in tumor detection; 
- Improved bioavailability: opsonins, immune system proteins, are the proteins in 
charge of activating the immune complement to mark the NPs for destruction by macrophages 
and other phagocytes (27). Opsonins recognize less neutral NPs than charged particles, and 
hydrophilic particles less than hydrophobic particles. It is possible to design NPs to be neutral 
or conjugated with hydrophilic polymers (such as polyethylene glycol - PEG) to prevent 
opsonization, prolonged circulation time, reduce RES uptake, and/or enhance 
biocompatibility (28) (29). 
- Controlled release: NPs can also be designed to be activated to release therapeutic or 
diagnostic molecules in response to a site-specific trigger such as pH, temperature, magnetic 
field, enzymatic activity, and light or radiofrequency signals (14). For example, the acidic 
environment inside inflammatory and tumor tissues (pH 6.8) and cellular vesicles, such as 
endosomes (pH 5.5–6.0) and lysosomes (pH 4.5–5.0), can be exploited to trigger drug release 
(30).  
Nanoplatforms are commonly classified in some principal categories: the most widely used 
are dendrimers, micelles, nanotubes, nanoshells, liposomes, and polymeric nanoparticles 




Figure 1. Schematic Representation of Nanoparticles. A. Dendrimers. B. Micelles. C. Nanotubes. D. Nanoshells. E. 
Liposomes. F. Polymeric nanoparticles. 
 
Figure 1A depicts the schematic of dendrimers. They are branched polymeric macro-
molecules forming a star-like structure made of a repetition of starting small units (31) (32) 
(33). Dendrimers present a size ranging from 1 to 20 nm and due to their dimensions, they are 
rapidly uptaken by cells and provoke a reduced activation of the immune system. Their 
propensity to form complex with biomolecules present in the circulation limits their use in 
clinic.  
Micelles (Figure 1B) are composed by an inner hydrophobic core, suitable for the entrapment 
of non-polar molecules, and an external hydrophilic layer, crucial for their solubility in 
aqueous solutions. They are made of a single layer of phospholipids and present a size of 
about 7-35 nm. The main advantage in their use is the great easiness of the synthesis process. 
However, the main limitation concerns their impossibility to transport hydrophilic molecules 
(34). 
Carbon nanotubes, depicted in Figure 1C, are composed of a distinct molecular form of 
carbon atoms that give them unusual thermal, mechanical, and electrical properties (35). If 
modified with PEG, they are surprisingly stable in vivo, with long circulation times and low 
uptake by the reticuloendothelial system (RES).[48] Carbon nanotubes have been used for the 
delivery of imaging and therapeutic agents and in the transport of DNA molecules into cells.  
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Carbon nanoshells (Figure 1D) are composed of a silica core that is covered by a thin metallic 
shell, usually composed of gold. Their primary use is in thermal ablation therapy but they also 
scatter light, a property which is useful for cancer imaging (36). 
Nevertheless, the most common drug delivery systems are liposomes and polymeric 
nanoparticles. 
Liposomes (Figure 1E) are constituted by one or multiple lipid double layer and thus, in the 
latter case, present two aqueous phases, one in the core and one between the bi-layers in 
which it is possible to entrap polar molecules (37). Instead, non-polar molecules can be 
loaded in the lipid bilayer. To increase their circulation half-life, liposomes can present also 
PEG in the external layer and this addition has been shown to increase by ten-fold the 
circulation half-life of liposomes (38). Moreover, by using lipids of different fatty-acid-chain 
lengths, scientists can construct liposomes to be temperature-sensitive or pH-sensitive, 
thereby permitting the controlled release of their contents only when they are exposed to 
specific environmental conditions. In 1995, “Doxil”, the first liposomal platform has been 
approved by FDA as therapeutic agent for the treatment of AIDS-associated Kaposi’s 
sarcoma. It represents a liposome formulation loaded with Doxorubicin (39) (40). 
Finally, polymeric nanoparticles (Figure 1F) are colloidal system realized by amphiphilic 
molecules. This platform usually presents a spherical-like structure with a size range of 
approximately 50-250 nm.  Generally a block of co-polymers is used to have both the 
hydrophobic and the hydrophilic part. Based on the synthesis procedure, it is possible to 
obtain two different systems: nanoparticles with a polymeric hydrophobic core and 
nanoparticles with an aqueous core surrounded by the polymer (22). Several clinical studies 
have already used polymeric nanoparticles (41). The choice of the material used is 
fundamental for the physico-chemical characterization, the pharmaco-kinetic properties, and 
the biodegradability of NPs. Biodegradable polymers are of particular interest, since they can 
be fully metabolized and removed from the body, creating non-toxic NPs (42). Poly-lactic-co-
glycolic acid (PLGA) is an especially intriguing example of a biodegradable polymer, since 
relative proportions of his components, polylactic acid (PLA) and polyglycolic acid (PGA), 
can be used to tune the biodegradability of PLGA (43).  
More recently, another nano-platform has been developed. It consists of an inner hydrophobic 
core made of the polymeric matrix (PLGA) and an external layer made of lipids monolayer. 
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Some of these lipids are also conjugated with PEG to stabilize more the nanoparticle in 
circulation (28) (29). This platform combine higher rate of loading efficiency of non-polar 
molecules, but presents also a lipid layer to resemble more to biologic vesicles (44). 
 
2.1.2. Three major challenges to improve the Nanoparticles performance 
Nanoparticles for the systemic delivery of therapeutic agents and imaging passed the 
preclinical studies for treatment and cancer detection (45). Compared to the free drugs, agents 
loaded within nanoparticles (nanomedicines) enhance the bioavailability and blood longevity, 
increase the protection against degradation and promotes higher accumulation and controlled 
release at biological targets. In addition, nanoparticles can carry multiple and different agents, 
for the combination therapy (46) (47), multimodal imaging (48) (49) and theranostics 
(combined delivery of therapeutic agents and imaging (50) (51)). Despite all of these 
advantages, nanomedicines are yet to be fully part of clinical therapy. In the process of 
improving the performance of systemically injected nanoparticles, three major challenges 
should be addressed: i. increasing loading efficiency and controlled release of therapeutic 
molecules; ii. mitigating recognition by the mononuclear phagocytic system (MPS); iii. 
enhancing tissue-specific accumulation.  
Over the last 15 years, a large number of different nanomedicines have been proposed. Yet 
amounts of encapsulated drugs are still a minor portion of the overall nanoparticle mass, 
leading to inadequate loading efficiencies. In most lipid or polymeric-based delivery systems, 
only up to 10% of the nanoparticle mass is constituted by active therapeutic agents (52) (53). 
Indeed, the drug, in order to achieve therapeutically effective doses, is administered in a large 
mass of inert materials. This inadequate loading efficiency could lead to a local or systemic 
toxicity, especially due to the large amount of material to be administered.  
The second challenge is related to the modulation of the nanoparticles interaction with the 
MPS. Nanoparticles are seen as foreign objects and they tend to be rapidly coated by opsonins 
from the complement system that facilitate their recognition and sequestration by professional 
phagocytic cells, mostly located within the liver (Kupffer cells) and the spleen (splenic 
macrophages) (54) (55). Results from biodistribution studies indicated that over 50% of the 
injected dose of nanoparticles is trapped into filtering organs (liver and spleen) (56) (57) (58) 
(59) (60) (61).  
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Non-specific MPS sequestration is closely linked with the third challenge, which is related to 
enhancing the accumulation of injected nanoparticles at the biological target. Importantly, a 
recent retrospective study documented that, on average, only 0.7% of the injected 
nanoparticles actually reach the neoplastic mass (62). Therefore, starting from these 
considerations, with this work we tried to make a contribution to reduce “the nanoparticles 
weaknesses”. 
2.1.3. The Current Paradigm in Cancer Nanomedicine Design 
In preclinical animal models Maeda et al. (10) observed that the rapid tumor vascularization is 
characterized by a discontinuous endothelium and exhibit irregular openings (fenestrations) 
ranging in size in the few hundreds of nanometers scale. Consequently, through these 
fenestration, sufficiently small nanoparticles could passively penetrate and be retained within 
the tumor, following a process named the enhanced permeability and retention (EPR effect) 
(10). Furthermore, longer circulation half-lives may enhance the tumor accumulation (the 
number of passages into the diseased vasculature would increase). Inspired by the EPR effect 
and the need for long circulation times, a large number of nanoparticles for cancer treatment 
and imaging are synthesized with a spherical shape, an average diameter of 100 nm, and a 
surface mostly decorated with polyethylene glycol (PEG) chains. Currently, this is the major 
paradigm for cancer nanomedicine design. Referring on the self-assembly, organic materials 
have been used, such as lipids, polymers, block copolymers, and combinations thereof, as 
well as non-organic materials, such as iron oxide, gold, silver, and carbon-based materials 
(63) (64) (65) (66) (67) (68) (69) (70). Despite such an incredibly large number of 
formulations, tumor deposition is about 1% on average of the injected dose (62).  
2.1.4. Biological Inspiration in Cancer Nanomedicine Design 
 
After injection, nanoparticles are transported by hemodynamic forces into the blood vessels. 
On the way, nanoparticles are surrounded by a multitude of cells and molecules, including the 
abundant red blood cells (RBCs) occupying from 40% to 50% of the vascular volume. Under 
flow, deformable RBCs tend to accumulate within the vessel core, leaving a “cell-free layer” 
next to the walls (Figure 2) (71). The leukocytes and platelets, which are much less abundant 
than the RBCs, are pushed laterally towards the wall, in the area we have just called "cell-free 
layer". This behavior facilitates the wall adhesion, and extravasation of leukocytes and 
platelets. This is particularly relevant at sites of inflammation, where leukocytes abandon the 
vascular district and invade the tissue (72) (73) (74). Taking inspiration from these 
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phenomena, one of the solutions could be the design of particles that margin in the cell-free 
layer such as leukocytes and platelets and efficiently reach vascular abnormalities, such as the 
presence of fenestrations. However, since RBCs form a very compact block of cells in the 
core of the vessel, only the fairly large particles would be pushed laterally near the vessel 
wall. Small particles (10-500 nm) would move quite comfortably between the red blood cells 
and accumulate less efficiently in the cell-free layer (Figure 2) (75). 
 
Figure 2. (Lee T. R. et al., 2013)Distribution of Red Blood Cells and Nanoparticle accumulation within the Tumor 
Parenchyma Vascular.  RBCs tend to accumulate within the vessel core, leaving a cell-free layer next to the wall.  
Nanoconstructs with comparable in size to RBCs (0.8-9µm), tend to be pushed laterally and accumulate within the cell-free 
layer next to the vessel walls. In contrast, small nanoparticles can find their way within the shoal of RBCs and tend to be 
distributed quite uniformly across the blood vessel (75). Small nanoparticles passively cross the endothelial fenestrations and 
accumulate in a perivascular position. Sub-micrometric and micrometric nanoconstructs, which are sufficiently deformable, 




 Furthermore, particles of non-spherical shape, such as cylindrical or discoidal would increase 
the likelihood of border and escape the flow of RBCs. Therefore, aiming at enhancing lateral 
margination, one could design particles with size similar to platelets and with a non-spherical 
shape. 
Another challenge consider  is the realization of adherent particles. It is important to underline 
that the tumor microvasculature has different biophysical characteristics compared to healthy 
tissues. The average speed is one order of magnitude lower than in normal vascular networks 
due to greater hydraulic resistance and lower perfusion (8). Moreover, the tumor capillaries 
express specific and more abundant endothelial receptors (76). Then, the right combination of 
particles size and shape is crucial for the adhesion to the tumor microvasculature. In 
particular, discoidal and cylindrical particles expose a greater surface area for adhesion to the 
vessel wall and therefore have the possibility of establishing more molecular bonds and 
colloidal interactions with endothelial cells than spherical particles. In addition, the 
hemodynamic displacement forces from the RBCs flow would be less effective on adherent 
particles. Therefore, referring to a given volume, the non-spherical shape is fundamental to 
maximize interactions with endothelial cells and minimize the hemodynamic displacement 
forces (figure 2) (77) (78). Another alternative might seem the realization of small but discoid 
shaped particles. Those particle would feel, like the spherical ones, the hemodynamic forces 
of displacement and would easily settle even in healthy capillaries giving a non-specific 
release. The larger size solves this problem because large cylindrical particles would be 
affected by the displacement force not only in healthy vessels but also in tumor vessels. Upon 
arriving at the tumor site, they would accumulate and release the drug more easily due to the 
tortuous capillaries. Therefore, within the tumor vasculature, we would have a preferential 
deposition of submicrometric particles with cylindrical or discoidal shape. In recent years, this 
discovery has led to the development of sub-micrometric release particle systems. For 
example, discoid mesoporous silicon particles have been designed, which tend to 
preferentially release in the tumor site due to a favorable balance between adhesion and 
dynamic marginalization (78) (79) (80) (81). More recently, Merkel et al. (82) (83) have 
introduced long - circulating particles which mimic the RBCs. In fact, the administration of 
micrometric and submicrometric particles mainly raises concerns such as: sequestration from 
macrophages, difficulty in crossing the tumor endothelium and limited blood longevity. 
However, these concerns could be addressed by employing deformable particles. But, 
deformable particles with RBCs size would travel within the vessel core together with RBCs, 
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decreasing the probability of extravasation and release. However, instead particles in the sub-
micron to micron size range would be pushed laterally by the abundant RBCs flow and 
confined to moving in the cell-free layer bouncing between endothelium and RBCs (Figure 
2). Also, deformable particles would squeeze and navigate better through smallest cerebral 
capillaries and in the lungs and spleen microcirculations (82) (83). Moreover the resistance of 
deformable particles to macrophage uptake would limit their sequestration by Kupffer cells 
(11). On the other hand, the smaller particles can be rapidly absorbed by the Kupffer cells and 
easily permeate the discontinuous hepatic endothelium and end up in the Disse space. To 
conclude, the deformable particles are able to squeeze and infiltrate in the abnormal 
fenestration of tumor capillaries and circulate in the blood for a long time, like platelets and 
RBCs. 
2.1.5. top-down synthesis approach 
 
Spherical nanoparticles are generally synthesized by favoring the self-assembly of molecules, 
polymeric chains or grains under vigorous steering (84) (85) (86). Differently, non-spherical 
particles are fabricated via a top-down approach, involving techniques widely utilized in the 
microelectronic industry. Very few research groups have documented the fabrication and in 
vivo application of non-spherical particles for biomedical applications. Well known are the 
works presented by the groups of Ferrari (87); De Simone (88); Mitragotri (89); and Park 
(90). Sub-micrometer mesoporous silicon particles with a quasi-hemispherical, discoidal and 
cylindrical shape were fabricated by Ferrari and collaborators combining optical lithography 
and electrochemical etching (91). De Simone and co-workers have demonstrated differently 
shaped nanoparticles with a characteristic size as small as 200 nm, utilizing a proprietary 
methodology known as PRINT (particle replication in non-wetting templates) (92) (83). 
Mitragotri’s group has utilized mechanical stretching and the intrinsic viscoplastic properties 
of several polymers to morph the shape of originally spherical micron-sized particles (89). 
The laboratory of Park has developed a sacrificial hydrogel template approach to synthesize 
variously shaped particles, mostly in the micron-sized regime, for controlling the long term 
release of therapeutic agents (90) (93).  
Key et al. (94) presented a novel top-down approach for the facile synthesis particles with a 
precise control on size, shape, surface properties, and mechanical stiffness. The approach was 
demonstrated for the production of discoidal polymeric nanoconstructs (DPNs). Importantly, 
this platform shown an unprecedented blood longevity and accumulation within the tortuous 
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tumor neovasculature. The sub-micrometric size and deformability of discoidal polymeric 
nanoconstructs minimizes permeation across the liver endothelium and the non-specific 
sequestration by hepatic Kupffer cells. 
 
2.2. Focus of the work 
Considering the mentioned promising results about the DPNs we can say that this platform 
could put into practice the above-described notions of marginating, adhering, and deformable 
nanoparticles. However, the production method was time and resources consuming. In 
addition, the nanoconstructs yield was around 13% respect to the theoretical number. 
Furthermore, the encapsulation efficiency was around 1%.  
The first aim of my PhD project was to enhance DPNs production and DPNs properties in 
term of stability in circulation, ability to reach the targeted cells and to load and release the 
drug more efficiently, avoiding the sequestration from phagocytic cells of the immune system. 
Moreover the pharmacological properties of DPNs were finely tuned by changing the loading 
strategies and compound properties (hydrophobicity and molecular weight). 
Specifically here, a hybrid fabrication strategy, combining nanoscale lithographic techniques, 
wet etching, and polymer chemistry, was developed to tailor the size, shape, surface 
properties, and mechanical stiffness of nanoconstructs. This strategy is more precise, 
reproducible, quicker and more efficient than the previous one. Going into details the 
nanoconstruct geometry (size and shape) is imposed with a master silicon template, which is 
realized via direct laser writing for sub-micron to micron sizes (5000 nm to 600 nm). Circular, 
rectangular, elliptical, hexagonal, square, triangular, and other shapes can be readily realized. 
Nanoconstruct thickness can also be modulated by properly adjusting the etching of the 
silicon wafers. The nanoconstructs are obtained by polymerizing a mixture of poly(lactic-co-
glycolic acid) (PLGA) and PEG chains in a sacrificial template (imposed with the silicon 
master template), which is then dissolved in water under gentle agitation. Polymer 
concentrations affect the hydrophobicity of the particles matrix, thus influencing water 
content and deformability. Low PEG concentrations lead to more hydrophobic matrices, 
which are characterized by reduced swelling and lower deformability, whereas high PEG 
concentrations lead to more hydrophilic matrices, which are associated with increased 
swelling and higher deformability. 
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Atomic force microscopy can be conveniently used for testing the mechanical properties of 
these nanoconstructs, whose Young’s modulus can vary from a cell-like value (Young’s 
modulus of 10 kPa) to that of more rigid blocks (Young’s modulus on the order of 10 MPa). 
Furthermore, these nanoconstructs are constituted by polymer matrices comprising both 
hydrophobic and hydrophilic micro-domains that serve as pockets for a variety of therapeutic 
and imaging molecules. Surface properties can be readily modified after releasing 
nanoconstructs and activating PLGA terminations for chemical conjugation with antibodies, 
peptides, aptamers, and various other ligands. Also, lipid and polymer-drug conjugates and 
contrast agents can be readily incorporated within these polymeric matrices, leading to the 
development of theranostic agents. Moreover, as we said above, the encapsulation of 
therapeutic into nanoparticles has substantial impact in clinical medicine.  The traditional 
approach, based on DPNs direct loading, where therapeutic and imaging agents are dispersed 
within the polymeric paste and directly loaded into the wells of the template, demonstrated 
often inefficient, leading to low encapsulation values. In this project was enhanced the 
encapsulation and stability of payloads of DPNs: was identified a new loading strategy for 
achieving encapsulation efficiencies well above 80%.  In particular, we developed a new and 
innovative drug loading system using the absorption effect of the polymeric matrix to 
intercalate the drug with the polymer. In addition, Ferreira et al did a systematic analysis of 
the loading and release for a variety of imaging and therapeutic agents loaded into DPNs. Six 
different compounds were realized by conjugating directly 1,2-Distearoyl-sn-glycero-3-
phosphorylethanolamine (DSPE) lipid chains or 1 kDa PEG chains with the near-infra red 
molecules Cy5.5 or the chemotherapeutic molecules methotrexate (MTX) and doxorubicin 
(DOX). The resulting six compounds present different molecular weights and hydrophobicity 
levels as compared to the original, unconjugated molecules. The six compounds are entrapped 
within the polymeric matrix of DPNs using both loading strategies (the old and the new one); 
and the encapsulation efficiencies and release profiles are consequently assessed. Finally, the 
pharmacological properties of DPNs are documented in vitro on triple negative breast cancer 






1.1. Methodologies   
 
1.1.1. Fabrication of DPNs silicon master template 
 
Discoidal polymeric nanoconstructs were synthesized by employing a top-down fabrication 
process that can be split into four main phases that during this work were analyzed separately: 
spin coating, laser writing, deep reactive ion etching, and silanisation (fig. 3).  
 
Figure 3. The four main steps of the silicon master template fabrication: (a) spin coating, (b) laser writing, (c) deep 
reactive ion etching and (d) silanisation.  
 
The first step is related to the use of the Direct Writer Lithographic (DLW) technique to 
fabricate a silicon master template presenting an array of holes with circular, elliptical, and 
quadrangular base and fixed size. The geometrical pattern of the template was drawn using 
the LASI software. The drawing was converted from GDS format to HIMT format. An 
AZ5214E resist was written via a laser writer system at 405 nm (Heidelberg  Instruments  
DWL66FS). The wafer (4 inches, doped P, 525 x 25 μm) was first washed through sonication 
in acetone and isopropanol. The primer and the resist were deposited over the silicon wafer by 
spin coating (Sawatec) using the following protocol: 10 sec at 500 rpm and 60 sec at 4,000 
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rpm, resulting in a final thickness of about 1.4 µm (fig. 3a). This coating was baked on a hot 
plate at 110 °C for 1 min. Then, with the instrument Heidelberg Direct Writer Lithography, an 
exposure job was set up with a defocusing value of 1,700 nm and laser intensity of 0.75 
mWatt (fig. 3b). The substrate was developed with AZ726 developer for 4 min. The pattern 
was transferred to the underlying silicon substrate by deep reactive ion etching with SF6/O2 
plasma for 60 sec (Sentech SI500 Instrument GmbH  RIE) (fig. 3c). The resist was removed 
in a piranha solution (sulfuric acid and hydroxide peroxide (3:1)) for 5 min. The Silicon 
Template was sinalised to avoid interaction between the silicon template structured and 
silicone materials such as PDMS. An oxygen plasma (pressure 0.5 mBar, stabilization 15 sec, 
time 1 min, Oxygen (%) 100, frequency 100 W) was made on the silicon master template 
followed by silanization with 125μl of CF3(CF2)5(CH2)2SiCl3 for 1 hour under reduce 
pressure (fig. 3d). The resulting silicon master template was imaged with Scanning Electron 
Microscopy (Helios Nanolab 650 Dual Beam, Fei company).  
1.1.2.  PDMS and PVA sacrificial templates 
Once the silicon master template was obtained, the following step requires the realization of a 
polydimethylsiloxane (PDMS) replica. The silicon master template was fixed on a Petri dish 
(d=10 cm). A solution of PDMS and curing agent (10:1) was cast over the Si wafer.  The 
mixture was then polymerized at 60° for 3 h. This resulted in a second template, presenting 
cylindrical pillars on his configuration (fig. 4.2 left). This process was repeated seven times to 
generate seven PDMS templates. The templates were fixed into a petri dish (d=15 cm) and 
covered with ~30 mg of PDMS (10:1) to form a unique structure with the size of a Petri dish. 
The final step required the realization of a sacrificial template of poly(vinyl) alcohol (PVA). 
A 5% PVA solution was deposited over the PDMS replica template. Was left to dry in an 
oven for 3h at 60°C, the PVA solution became a thin film. Upon complete drying and was 
peeled off the PDMS template (fig. 4.2 right). This template presented circular wells, just like 
the original master Si template (fig. 4.2 middle).  
1.1.3.  DPNs Fabrication 
For the synthesis of soft DPNs (s-DPNs), 30 mg of poly(lactic-co-glycolic acid) (PLGA)  
were dissolved in chloroform (CHCl3) and mixed with 6 mg of polyethylene glycol (PEG) 
diacrylate  and 10 μg of 2-Hydroxy-40-(2-hydroxyethoxy)-2-methylpropiophenone 
(photoinitiator).  For rigid DPN (r-DPNs) synthesis, 90 mg of PLGA was dissolved in CHCl3 
with the same co-constituents described above. Instead, for rigid rigid DPN (rr-DPNs) 
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synthesis was always used a tripled PLGA concentration but removing PEG and Photo-
initiator. 30 µg of DSP-CY5 or Lipid rhodamine B (Avanti Polar Lipids, USA) was also 
added for providing proper fluorescent optical contrast. The resulting polymeric paste was 
carefully deposited in the wells of the sacrificial PVA template (fig. 4.3 left) and exposed to 
UV-light for polymerization (fig. 4.3 middle). The resulting PVA film, loaded with the above 
polymeric paste, was immersed in water and left to stir for 3h. This step led to the dissolution 
of the PVA and the release of DPNs in the aqueous solution (fig. 4.3 right). DPNs were 
eventually collected via centrifugation and membrane filtration to remove residual fragments 
of PVA.  
 
Figure 4. DPNs  Fabrication steps. 1) Realization of a silicon master template; 2) Soft Lithography (PDMS and  PVA 
replication); 3) DPN fabrication (loading of the PLGA/PEG mixture, polymerization, sacrificial template dissolution and 
DPN collection). 
 
1.1.4.  DPNs loading  
Two loading protocols were developed, namely, direct and absorption loading. In “direct 
loading”, the imaging and/or therapeutic agents of interest were dispersed within the original 
polymeric paste and directly distributed in the wells of the PVA template. In “absorption 
loading”, the collected DPNs were lyophilized to form a powder. This was eventually 
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dispersed in an aqueous solution carrying the imaging and/or therapeutic agents of interest. 
Re-hydration led to the rapid absorption of the molecules within the hydrogel structure of 
DPNs. The concentration of DPNs, imaging agents, and therapeutic molecules, the volume of 
the aqueous solution was systematically varied to identify optimal loading conditions. 
1.1.5.  DPNs Characterization 
The size and shape characterization was done on all silicon master templates, PDMS replicas 
and the particles from the four different DPN configurations by Scanning Electron 
Microscope Helios Nanolab 650. Ultra-high resolution SEM images were acquired at high 
vacuum conditions after 10 nm aurum coating using a Q150T ES sputter-coater (Quorum). 5 
~ 25 keV of beam energies and corresponding electron currents of 0.98 pA ~ 0.14 nA were 
used. In all cases, the mode 2 configuration was used.  
DPNs still embedded within the PVA templates were observed using an A1+ confocal 
microscope (Nikon-A1, Nikon corporation Japan) equipped with 63X lens working in oil 
immersion (an additive 1.5X optical magnification was applied). Lipid rhodamine B (Avanti 
Polar Lipids, USA) was used in the fabrication step to allow particle visualization.  
DPN concentration and size distribution profiles were performed through a multisizer 
(Beckman Coulter, USA). The ζ-potential was calculated using DLS (Malvern, UK). 
Morphological analysis of DPNs was also determined by TEM (JEOL, Japan). TEM samples 
were prepared by the drop-casting method over a carbon-coated grid, were sputtered with 10 
nm of carbon and analyzed operating at an acceleration voltage of 100 kV. The DPNs solution 
was placed and dried on a carbon-copper grid, and was carbon coated with 10-20 nm before 
Transmission Electron Microscope imaging (JEOL JEM 1011 TEM working at 100KV). 
1.1.6.  AFM Young Modulus/stiffness analysis 
The mechanical properties of DPNs were tested using a Nanowizard III AFM system (JPK 
Instruments, Germany), mounted on an AxioObserver D1 (Zeiss, Germany). Silicon nitride 
triangular cantilever (DNP, Bruker, USA), with a nominal spring constant of 0.06 N/m, was 
employed. The typical radius of curvature of the tip was 20 nm. The actual spring constant 
was determined in situ for each cantilever using the thermal noise method (Hutter & 
Bechhoefer, 1993). QI Advanced software module was included in the setup. QI data set were 
acquired in milliQ water, by applying maximum forces load between 1 nN and 2 nN. Force-
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distance (FD) curves length was maintained constant for each data collection, ranging from 
0.5 µm to 1 µm, the tip was always moved at a constant velocity of 17 µm/s.  
FD curves were analyzed by using the JPK Data Processing software (JPK Instruments, 
Germany). Each FD curve of the QI map was converted into force-indentation (FI) curve and 
fitted with the Hertz model, by using a Poisson’s ratio of 0.5. The AFM tip was approximated 
as a quadratic pyramid indenter.  
Three different polymeric paste compositions were prepared to produce: soft DPN (sDPN), 
rigid DPN (rDPN) and rigid rigid DPN (rrDPN). In particular, the preparation of the polymer 
paste for the sDPN, rDPN and rrDPN synthesis has been described in the section 2.3 DPNs 
Fabrication. 10 μL sDPN, rDPN, rrDPN colloids ( 1000 nm of diameter × 400 nm of 
thickness discs with a circular base) were deposited on Poly-L-Lysine coated glass substrates 
(HistoBond + 76 x 26 x1 mm; Marienfeld). The sample was dried at room temperature and 
subsequently rehydrated in milliQ water, for at least 3 h prior the AFM data acquisition. 
Atomic force microscope and the Young’s modulus was calculated by analyzing the resulting 
force-displacement curves. 
 
1.1.7.  Prodrugs synthesis 
Conjugating lipid chains - Cyanine-5 (DSPE-Cyanine-5), DSPE-Cy5-A, and DSPE-Cy5-B 
(near-infrared imaging agents Cy5.5) were synthesized as reported by Lee and coworkers with 
some modifications (95). 15 mg of DSPE-NH2 were dissolved in 3 mL of dichloromethane 
(DCM) and 1.5 mL of MeOH. 0.98 eq of Cyanine-5 NHS ester was dissolved in 200 ml of 
dimethylformamide (DMF) and added to the previous solution. A catalytic amount of 
triethylamine (TEA) was added to the reaction and left to stir for 16 hours. The resulting 
product was precipitated with cold diethyl ether, then washed 3 times with cold diethyl ether 
obtaining the final compound with a yield of 90%.   
DSPE-Methotrexate. 15 mg of DSPE-NH2 were dissolved in 3 mL of dichloromethane 
(DCM) and 1.5 mL of MeOH. 0.98 eq of Methotrexate ester was dissolved in 200 ml of 
dimethylformamide  (DMF) and added to the previous solution. A catalytic amount of 
triethylamine (TEA) was added to the reaction and was left to stir for 16 hours. The intended 
product was precipitated with cold diethyl ether, then washed 3 times with cold diethyl ether 
getting the final product with a yield of 90%.   
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PEG-Methotrexate. 20 mg of PEG-NH2 (1,000 Da) were dissolved in 3 mL of 
dichloromethane (DCM) and 1.5 mL of MeOH. 0.98 eq of Methotrexate was dissolved in 200 
ml of dimethylformamide (DMF) and added to the previous solution. A catalytic amount of 
triethylamine (TEA) was added to the reaction and was left to stir for 16 hours. The intended 
product was precipitated with cold diethyl ether, then washed 3 times with cold diethyl ether 
getting the final product with a yield of 90%.   
Linoleic acid-doxorubicin. LA-Dox was synthesized as reported by Fernandes and coworkers 
with some modifications (96). Briefly, an aqueous solution of Doxorubicin hydrochloride (5 
mg/mL) was neutralized with a solution of sodium bicarbonate solution (50 mg/mL). A 
linoleic acid solution (50 mg/mL) in ethanol was incubated with EDC/NHS (molar ratio of 
3:1) for 1 h under magnetic rotation at room temperature. The obtained solution was added 
drop by drop to the above mixture while stirring. After 12h, the mixture was centrifuged 
(12,7000 rpm, 30 min). The red pellet was washed with distilled water three times, removing 
the unreacted water-soluble Doxorubicin. Finally, the red pellet was collected and dried under 
vacuum.  
DSPE-doxorubicin. An aqueous solution of Doxorubicin hydrochloride (5 mg/mL) was 
neutralized with a solution of sodium bicarbonate solution (50 mg/mL). A DSPE-succinic-
acid (50 mg/mL) in ethanol was incubated with EDC/NHS (molar ratio of 3:1) for 1 h under 
magnetic rotation at room temperature. The obtained solution was added drop by drop to the 
above mixture while stirring. After 12h, the mixture was centrifuged (12,7000 rpm, 30 min). 
The red pellet was washed with distilled water three times, removing the unreacted water-
soluble Doxorubicin. Finally, the red pellet was collected and dried under vacuum. 
1.1.8.  Loading and release studies 
To calculate the amount of drug inside DNPs, samples were lyophilized and dissolved in 
acetonitrile (ACN). All samples were analyzed by HPLC at 240 nm UV absorbance (Agilent 
1260 Infinity, Germany). The encapsulation efficiency was defined as the percentage weight 
ratio between the drug amount loaded inside DPNs at the end of their preparation and the 
initial input amount of the drug. For the release studies, 200 μL of DPN solution was poured 
into Slide-A-Lyzer MINI dialysis microtube with a molecular cut off of 10 kDa (Thermo 
Scientific) and dialyzed against 4L of H2O at 37 °C. For each time point, in triplicate, DPNs 
were collected and destroyed with ACN to release the molecule of interest. Samples were 
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analyze depending on an HPLC (Agilent 1260 Infinity, Germany) at 340 nm UV absorbance 
for MTX prodrugs, and 490 nm and 646 for LA-Dox and Cy5 respectively. 
1.1.9.  Cell culture and viability 
The human Triple Negative Breast Cancer MDA-MB231 cell line was obtained from the 
American Type Culture Collection (ATCC). Cells were cultured in Eagle's minimal essential 
medium (EMEM) (ATCC,USA) containing 10% FBS (Gibco, Thermo Fisher Scientific, 
USA), 1% penicillin/streptomycin (Sigma-Aldrich, USA), under a humid atmosphere (37°C, 
5% CO2, 95% air). Upon reaching appropriate confluence, cells were passed. Cell viability 
was determined via an MTT assay, which detects the reduction of MTT (3-(4,5-
dimethylthiazolyl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich, USA) by mitochondrial 
dehydrogenase to blue formazan product. This reflects the normal function of mitochondria 
and, hence, the measurement of cytotoxicity and cell viability. Briefly, 2x105 cells/well were 
seeded in 96-well plates and incubated at 37°C, 5% CO2, for 24 h. Next, the medium was 
replaced with EMEM containing the corresponding concentrations of Doxorubicin (DOX), 
doxorubicin pro-drug (LA-DOX, DSPE-DOX, (LA-DOX) DPNs and (DSPE-DOX) DPNs) 
(0.1-50 μM), Methotrexate (MTX), PEG-MTX and DSPE-MTX (0-100 μM)) and (DSPE-
MTX) DPNs (0.01-0.5 μM). After 24h, 48h, 72h, and 96h of incubation, the MTT solution 
(5.0 mg/mL PBS) was added to each well and incubated at 37°C for 4h. The resulting 
formazan crystals were dissolved by adding ethanol (200 μL/ well), and the absorbance was 
read at 570 nm using a microplate reader (Tecan, CH). Controls (i.e.: cells that had received 
no drug) were normalized to 100% and readings from treated cells were expressed as 












2.1. Silicon master template fabrication  
A versatile fabrication strategy was used to realize polymeric nanoconstructs with controlled 
geometrical and mechanical features, including the size, shape, surface properties, and 
mechanical stiffness – the 4S parameters. These features can be independently tuned in the 
fabrication process to affect the therapeutic and imaging performances, as shown. (94). The 
silicon template appears as a matrix of wells reproducing the geometry of DPNs (fig. 7a). 
These wells represent the intended size and geometry of the desired nanoconstructs (fig. 8 a, 
b, c and d left and middle insets).  
In this work, we report the production of four different types of particles coming from a 
carefully optimization and improvement of the nanofabrication process. The precise geometry 
of the single particle derives from different silicon master templates obtained by laser writer 
and electron beam lithography. In particular, at first, the optimal resist was chosen, then we 
focused on the spin coating parameters, but the bulk of the work was done on the pattern 
design, the laser dose/defocus and the following silicon etching process. Generally, the laser 
writing lithography, since it can only work in proximity and not in contact, is used to direct 
writing and perform optical lithography masks with structures ranging from 5 µm to 10 mm. 
The dimensions of our structures are located into the resolution limits of the machine, so in 
our case, it is a delicate process susceptible to problems that will decrease the yielding and 
reproducibility. In fact, one of the most important goals achieved in this project was the fine 
calibration of the machine parameters and the pattern design according to the laser proximity 
diffraction limits.  
A pattern of wells has been designed on the silicon wafer in order to optimize the spaces and, 
therefore, the waste of material during the various phases of particle production. The gaps 
between the structures were at the machine's resolution limit and the number of structures 
designed was such as to cover the entire silicon wafer.  
The AZ 5214 E resist was chosen due to its excellent covering property during the ions 
etching process and its easy removal from the silicon wafer.  
The first problem identified was the optimization of the resist depth. In particular, if the 
obtained resist thickness was not optimal, the developer could not develop to the bottom of 
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the patterned wells, causing the shielding of silicon etching. In fact, the first objective was to 
find the right spin coating parameters to obtain a useful resist depth. Different spin coating 
speeds combined with different development times, and different concentrations of the 
developer were evaluated until reaching an optimal combination. 
Moreover, often during the development, the main issue was the detachment of the resist from 
the silicon wafer. This was solved by a preliminary primer deposition that prevented the 
detachment of the resist after development.  
In addition, the identification of the optimum defocus point for a certain resist thickness was 
crucial. An incorrect laser focusing often gives optical aberrations. Consequently, a correct 
defocus is a critical point of the reproducibility. A meticulous statistical work was done on 
this parameter in combination with different laser power doses. Indeed, the laser potency dose 
was another fundamental parameter for the technique reproducibility. Several power dose 
matrixes were made to define the useful laser potency. In particular, figure 5 shows an 
example of a laser matrix dose of 30%, 40% and 50% (at the fixed grey filter S30/10) 




Figure 5. Laser writer dose power matrix at three different wells nominal diameter (800 nm, 900 nm and 1000 nm). (a) 
experimental plan, (b) actual diameter at  30%, 40% and 50% of laser dose vs nominal diameter and (c) SEM images from 




 In figure 5a shows the detail experimental plan of the test, while in figure 5b, the two graphs 
and the table shows the variation of the diameter of the wells in function of the applied dose. 
Figure 5c is reported the SEM images of the 9 patterns obtained. It is possible to observe from 
the data that the nominal diameter at 900 nm combined with the doses 40-50% gives greater 
size homogeneity an actual wells diameter closer to 1000 nm. In the previous works of the 
group, this was seen as the optimal size of the DPN to adhere to the endothelial tight 
junctions. 
In figure 6 are reported the SEM images coming from the laser defocus optimization process. 
Results show that the combination of 50% of the laser dose with a defocus of 1800-1700 was 
able to create a more homogenous template, with holes with a diameter closer to 1000 nm. 
 
 




This type of calibration was performed for the four nanoconstructs configuration shown. 
This meticulous optimization work led to an increase in the size of the silicon master template 
and in an increment of the number of wells reproduced per template.  This led to an increased 
particle yielding production of 40 times for the same number of templates. 
Besides that, this work showed for the first time the possibility to use the DLW lithographic 
technique to fabricate a silicon master template presenting such a large array of discoidal 
wells with circular, elliptical, and quadrangular base and fixed size within the limits of 
resolution.  
2.2. DPNs Production 
In fact, the silicon master template is used as a mold to realize a PDMS replica. The PDMS 
replica exhibits arrays of pillars with the same geometry of the wells in the silicon template 
(figure. 4.2). Finally, a sacrificial PVA template is obtained by replicating the PDMS 
template. DPNs are made out of a mixture of poly(lactic-co-glycolic acid) (PLGA), 
polyethylene  glycol diacrylate (PEG-DA), photoinitiator (PI), and the therapeutic or imaging 
agent of interest. For the preparation of DPNs, the polymer mixture of PLGA, PEG-DA, and 
PI is directly applied and spread over the PVA template to fill the multiple wells (Figure. 4.3). 
This loaded template is then exposed to UV-light for the polymerization of PEG-DA chains. 
The resulted PVA templates spread with the polymeric mixture are shown in figure 7c by 
confocal images. Eventually, the PVA film is immersed in an aqueous solution and dissolved 
after stirring (Figure 4.3) to release the DPNs. The final steps, including centrifugation and 
filtration, are used to remove residual PVA fragments. Figure 7c presents confocal fluorescent 
images of a PVA template loaded with a mixture of PLGA/PEG and Lipid Rhodamine (LP-
Rhod). A uniform distribution of ‘red dots’ within the structure can be appreciated. These ‘red 
dots’ correspond to the DPNs before the dissolution of the PVA template and are loaded quite 




Figure 7. a) SEM images of the silicon templates; b) SEM images of the PDMS templates; c) Confocal microscopy images of 
the PLGA/PEG mix-loaded into PVA templates. 
 
Table 1. Dimensions of circular 1000 x 400 nm CPN, circular 2000 x 600 nm CPN, elliptical EPN and squared QPN 
silicon master templates. 











439,14 ± 30,5 
Diameter  





610,97 ± 33,2 
Minor axis   
1374,87  ±  18,6 
Minor axis   
2156  ± 19,5 
 
Thickness 
 425,14 ± 20,4 
Side  











2.3. Physico-chemical characterization of DPNs 
In this work, it is reported the production of four different types of nanoconstructs and each 
phase of the fabrication process has been thoroughly monitored. The figure 7a shows the 
silicon templates that are currently in use to obtain the four nanoconstructs configurations; in 
the upper right is displayed a zoom of the tilted wells into the pattern. The figure 7b shows the 
SEM images from the PDMS replicas, in the upper right a zoom of the tilted wells is also 
displayed; figure 7c reports the confocal images from the PVA templates loaded with the 
polymeric mixture in the four different configurations. On the different templates a careful 
statistical analysis of the dimensions was made which reported a good size homogeneity. In 
particular, the electron microscopy images show the actual geometry of DPNs that exhibits: 
an average diameter of 1,250 ± 19.36 nm and a height of 469.14 ± 27.5 nm for the 1000 x 400 
nm circular DPN (1000 nm CPN – fig. 7a); an average diameter of 1945,7 ± 19,24 nm and a 
height of 610,97 ± 33,21 for the 2000 x 600 nm circular DPN (2000 CPN – fig. 7b); an 
average of major axis x minor axis of  1374,87 ± 18,6 x 2156 ± 19,5 nm and a height of 
425,14 ± 20,4 nm for the 2100 x 1400 x 400 nm elliptical DPN (EPN – fig. 7c); an average 
side of 1035 ± 32,21 nm anda height of 605,02 ± 26,21 nm for the 1000 x 400 nm squared 
DPN (QPNs - fig. 7d). The precise dimensions of each template are shown in table 1. The 
analysis shows that for each intended nanoconstructs the structure produced in each silicon 
template presents similar size with variations lower than 1%.  
The precise geometry of each single particle coming from different templates was also 
monitored and analyzed. On figure 8, is displayed a close up by Confocal Microscopy where 
the side top view and side view of nanoconstructs; a 3D model reconstruction by Confocal 
Microscopy and a TEM tilted image for 1 µm circular shape nanoconstructs (8a); 2 µm 
circular shape nanoconstructs (8b); elliptical shape nanoconstructs (8c) and square shape 
nanoconstructs (8d). The TEM images of individual DPNs presented in Figure 8 offer details 





Figure 8. Confocal Microscopy images of DPNs showing top, lateral and 3D reconstructed views (left); TEM tilted images of 
DPNs (center); Size spectrum as derived by a multisizer coulter counter analysis and characteristic surface electrostatic by 
dynamic light scattering analyses (right inset) for CPN 1000 nm (a), circular CPN 2000 nm (b), elliptical EPN (c), and 
squared QPN (d). 
 
The DPN concentration and size distribution profiles were performed through a multisizer and 
the ζ-potential was calculated using DLS (fig. 8 right inset). The analysis with the multisizer 
allowed us to quantify precisely the number of nanoconstructs as well as returning a 
characteristic size for the differently shaped DPNs. Note that, given the nonspherical shape of 
DPNs, a size distribution was returned with a sharp peak, which represents the characteristic 
geometrical dimension of DPNs for that instrument. This is a very powerful tool to assess the 
quality and reproducibility of the nanoconstruct geometrical features and for precisely 
counting the particles. Similar observations can also be extended to the DLS profiles.  The 
characteristic size, resulting from the multisizer and DL machines, is summarized in figure 8 
right inset together with the ζ-potential measurements. 
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2.4. Mechanical Characterization of Discoidal Polymeric Nanoconstructs.  
Atomic force microscopy (AFM) analysis was used to determine the morphological and 
mechanical properties of DPNs (Figure 9). 
 
Figure 9.  Mechanical characterization of discoidal polymeric nanoconstructs. (a) Morphological analysis via atomic force 
microscopy documenting the size and shape of CPN, QPN, and EPN. (b) Distribution for the Young’s modulus for the four 
DPN geometries (1000 and 2000 nm CPNs, QPNs, and EPNs). A direct comparison of the Young’s modulus is provided in 
the summarizing bar chart in terms of mean ± SD. (c) Size spectrum of DPNs with different levels of softness as derived by a 




 A variation on the stiffness of the nanoconstructs was obtained, changing the composition of 
the polymeric matrix. An AFM analysis of Young Modulus and stiffness was performed on 
the polymeric nanoconstructs and on the film from which the different types of particles arise. 
The films were synthesized with the polymer proportions shown in paragraph 2.6. AFM 
Young Modulus/stiffness analysis of the Methodologies section, while the geometry of DPNs 
properly resembles that of the original silicon templates (fig. 7a).  The DPN morphology was 
assessed using an AFM quantitative imaging mode under wet conditions. Figure 9a shows the 
size and shape of 1000 × 400 nm circular CPNs, 1000 × 400 nm square QPNs, and 2100 × 
1400 × 400 nm elliptical EPNs. Still using atomic force microscopy, the Young’s modulus of 
DPNs was estimated directly from multiple (>100) force−displacement curves, generated on 
over 10 particles per experimental group. In particular, the histograms in Figure 9b report the 
Young’s modulus distributions for three differently shaped DPNs (1000 nm CPNs, QPNs, and 
EPNs) and DPNs with different mechanical properties (soft, sCPNs; rigid, rCPNs; and 
rigid−rigid, rrCPNs). The Young’s modulus was E = 185 ± 35 kPa for the 1000 nm sCPNs, 
195 ± 16 kPa for the 1000 nm QPNs, 56 ± 6 kPa for the 2000 nm sCPNs, and 476 ± 110 kPa 
for EPNs. Therefore, regardless of the size and shape, all soft DPNs returned a Young’s 
modulus close to ∼100 kPa. Only EPNs present a slightly larger Young’s modulus, which 
might be associated with its elongated shape and different polymerization rates. As the 
percentage of PEG in the original polymeric paste reduces, DPNs became stiffer and the 
Young’s modulus grew correspondingly. Therefore, for rigid DPNs, it follows E = 737 ± 28 
kPa for the 1000 nm rCPNs and 1606 ± 177 kPa for the 2000 nm rCPNs; for rigid−rigid 
DPNs, it results in E = 1907 ± 162 kPa for the 1000 nm rrCPNs and 5172 ± 902 kPa for the 
2000 nm rrCPNs. As summarized in the bar chart of Figure 9b, the Young’s modulus grows 
steadily moving from soft to rigid and rigid−rigid DPNs, regardless of their size. Interestingly, 
the change in rigidity of DPNs is also reflected in size distribution measurements performed 
with the multisizer (Figure 9c). Note that, in this instrument, particles dispersed within an 
isotonic solution are forced to flow across a small 20 μm capillary where each single passage 
is counted as an event. Rigid and rigid−rigid DPNs present a smaller variation in size 
distribution exhibiting quite sharp peaks and less broad distributions as compared to soft 
DPNs. This could be related to the DPN deformability under flow, whereby softer particles 
would deform more and take different orientations in the flow thus leading to a broader size 
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distribution as compared to stiffer particles. Potentially, this could be used as a high-
throughput approach to qualitatively assess the nanoconstruct deformability.  
It should be pointed out that through a new versatile microfabrication method and fine 
characterization, the size, shape, and surface properties of nanoparticles have been modified. 
The effect of nanoparticle size, shape, and surface properties on cellular uptake has been 
extensively investigated for its basic science and translational implications. This systematic 
work was done in order to modulate recognition and subsequent internalization by phagocytic 
cells into the following work of the group (97). Recently, softness is emerging as a design 
parameter for modulating the interaction of nanoparticles with cells and the biological 
microenvironment. In fact, Palomba et al. (97) demonstrated, regardless of the size and shape, 
that softer nanoconstructs evade cellular uptake up to 5 times more efficiently, by bone-
marrow-derived monocytes, as compared to rigid nanoconstructs. Soft circular and 
quadrangular nanoconstructs are equally uptaken by professional phagocytic cells (<15%); 
soft elliptical particles are more avidly internalized (<60%) possibly because of the larger size 
and elongated shape, whereas over 70% of rigid nanoconstructs of any shape and size are 
uptaken.  
 
2.5. Loading therapeutic and imaging agents into DPNs 
The dispersion of functional molecules, such as therapeutic and/or imaging agents, within the 
polymeric structure of DPNs (Figure 10A) was achieved following two different strategies: a 
“direct method”, where the agent is dissolved in the organic solvent and directly mixed with 
the PLGA and PEG prior to deposition over the PVA template; an”absorption method”, where 
the agent is dispersed in a higher concentrated water solution, which is then exposed to the 
lyophilized powder of DPNs. In direct loading, the agent needs to be soluble and stable in an 
organic solvent whereas, for the absorption method, the agent needs to be soluble in water 
without forming micellar structures at high concentrations. As such the different loading 
methods work with different functional agents.  DSPE-CY5-A was the first compound to be 
loaded into DPNs (Figure 10B). The Cyanine5 (Cy5) has the advantage of easy detection via 
fluorescent imaging and can be used in vivo too as a fluorescent imaging probe. DSPE-CY5-
A was synthesized by reacting 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-amino 
(DSPE-NH2) with Cy5 pre-activated with N-Hydroxysuccinimide (NHS) on the terminal 
carboxylic acid. The compound DSPE-CY5-A resulted in being less hydrophobic than the 
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free Cy5-A. A more hydrophobic Cy5, which lacks the sulfoxide groups, increased, even 




Figure 10.  Schematic representation of Discoidal Polymeric Nanoconstructs and prodrugs. A. Schematic representation of 
DPNs, highlighting their porous structure and entanglement of PLGA and PEG chains. B. Structural representation of the six 





The same protocol was used for the synthesis. Then, methotrexate (MTX) was considered. 
This is a therapeutic molecule originally developed as an anticancer drug that also exhibits 
strong anti-inflammatory properties. A similar protocol, as per the Cy5, was used to prepare 
the prodrug DSPE-MTX (Figure 10B). MTX was pre-activated with a mixture of DCC and 
NHS, before conjugation with DSPE-NH2. With MTX, the hydrophobicity of the resulting 
compound was modulated by changing the lipid chain DSPE with PEG 1 kDa (Figure 10B), 
to increase the hydrophilicity of the resulting MTX prodrug. The synthesis protocol was the 
same as described above. Then, Doxorubicin (DOX) was also considered. This molecule was 
used for its red fluorescent signal as well as for its well-known cell cytotoxic activity. In this 
case, the protocol to generate the DOX prodrug was modified, in that DOX has no carboxylic 
acid group available, but rather an amine group. Therefore, first, the hydrochloride form of 
DOX was neutralized with a solution of sodium bicarbonate. Then, linoleic acid was pre-
activated with EDC and NHS, and added to the solution.  
Given the low water solubility of the resulting compound, it was collected via precipitation. 
The same procedure was used for the preparation of the DSPE-DOX (Figure 10B), replacing 
the linoleic acid with the DSPE-succinic acid. After preparing all these compounds and 
prodrugs, the loading steps were performed. “Direct loading” is the most straightforward 
procedure. The main requirement for the agent to be directly loaded is its solubility and 
stability in organic solvents, like dichloromethane (DCM), chloroform (CHCl3), or 
acetonitrile (ACN). The compound is directly mixed with the original polymeric past forming 
the DPNs and applied over the PVA template. A drawback of this straightforward loading 
procedure is the low encapsulation efficiency (EE), which is due to the yielding in the 
preparation of DPNs and the hydrophilicity-hydrophobicity ratio of the loaded agent.  
As per the yielding, it should be noted that a portion of the loaded agent and polymeric paste 
are wasted during the deposition into the PVA wells. As per the hydrophilicity-
hydrophobicity ratio, it should be noted that more hydrophilic compounds (lower LogP) tend 
to rapidly escape the DPN polymeric matrix during the purification and collection steps that 
occur in water.  “Absorption loading“ consists in exposing a concentrated aqueous solution of 
the agent to the initially lyophilized DPNs. During the rapid re-hydration phase, DPNs avidly 
recall, within their polymeric structure, water enriched with the molecules of the 
therapeutic/imaging agent. A fine balance between compound hydrophilicity and 
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hydrophobicity is required for this loading strategy. Note that, after absorption, the higher 
molecular-weight hydrophobic prodrugs would tend to stay more trapped within the core of 
the DPNs as compared to their free counterparts, thus limiting their interaction with the 
aqueous environment. 
2.6.  Optimizing the “absorption loading” into DPNs 
Based on the above reasoning, the encapsulation efficiency (EE) into DPNs would vary for 
each prodrugs and loading strategy. In the “direct loading”, EE can be optimized by 
improving the filling of the wells in the PVA template and limiting the losses of polymeric 
paste out of the wells. This optimization process is out of the scope of this work. As per the 
“absorption loading”, three independent parameters can be systematically modified to 
modulate EE. These parameters are: the exposure time of the lyophilized DPNs to the aqueous 
solution (rehydration time); the mass of prodrug in the aqueous solution; the volume of the 
aqueous solution. For studying the influence of the rehydration time, lyophilized DPNs were 
exposed to a 20 μL concentrated solution of 1 mg/mL of DSPE-Cy5-B for 1, 3, 6 and 10 
minutes. After exposure, water was added to the mixture followed by a centrifugation step to 
remove the non-absorbed DSPE-Cy5-B. This was quantified via UV-Vis spectroscopy. The 
results showed that Cy5 loading stayed around 75% and no variation with the exposure time 
was observed (Figure 11A, left column). Also, DPNs size and z-potential did not change 
during the process demonstrating no damage following the rehydration step (Figure 11A, right 
column). Based on this data, one minute of rehydration time was sufficient to load a 
significant amount ofDSPE-Cy5-B. “Absorption Loading” is also affected by the volume of 
the aqueous solution and the concentration of the therapeutic agent. Therefore, after fixing the 
volume of DSPE-Cy5-B solution (20 μL) and the exposure time (1 min), the agent 
concentration was reduced from 1 to 0.9, 0.75, 0.5, and 0.25 mg/mL. Even in this case, the 
compound concentration did not significantly affect the loaded amount of DSPE-Cy5-B, 
which stayed around 75% (Figure 11B, left column). A modest change in DPNS size was 
observed with a decreasing concentration of the compound (Figure 11B, right column). At 
low concentrations, DPNs acquired a larger size (860 nm, at 0.25 mg/ml) compared to the 
higher concentrations (720 nm at 1 mg/mL). This could be related to the intercalation of the 
compound within the DPN polymeric matrix that would pull it towards the core resulting in a 
slightly smaller and more compact structure. The last independent parameter to be analyzed 
was the volume of rehydration. In this case, the compound concentration (1 mg/ml of DSPE-
Cy5-B) and the exposure time (1 min) were fixed, whereas the volume varied between 10, 20, 
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30, 50, 100 μL. Results show that with an increase of the volume, the loading of the DSPE-
Cy5-B decreases (Figure 11C, left column). Indeed, lower volumes mean more DSPE-Cy5-B 
located in the vicinity of the DPN surface, thus leading to higher loading upon absorption. 
DPN size and z-potential were not affected by the volume variation (Figure 11C, right 
column). 
Summing up, optimal loading via absorption can be realized by minimizing the rehydration 
volumes and maximizing the mass of the compound. Importantly, the compound should be 
sufficiently hydrophilic to be dispersed in water and moderately hydrophobic to stay within 
the DPN matrix upon exposure to the aqueous environment. Thus, for this loading strategy, it 
is crucial to realize prodrugs with the right hydrophilic-hydrophobic ratio and molecular 
weight. The bar chart in Figure 11D summarizes the results obtained in terms of EE for the 
different loading strategies and compounds. The DSPE-Cy5 A and B present high EE under 
the absorption loading strategy, reaching encapsulations as high as ∼ 80%. Because of the 
DSPE derivation, these compounds are slightly less hydrophilic and have a larger molecular 
weight as compared to the original free probes (Cy5 A and B). These two features favor their 
loading into the DPNs during the absorption phase and limit their rapid release during the 
purification steps. This ideal combination of hydrophobicity/hydrophilicity ratio and the 
proper molecular weight is not achieved with the MTX prodrugs. The DSPE-MTX is 
significantly hydrophobic, with a LogP of 13.84, and cannot be efficiently resuspended in 
water returning an EE= 1.2%. On the other hand, the 1 kDa PEG-MTX has a LogP of -3.31, 
which allows efficient resuspension in water. However, the large molecular weight of the 
resulting compound opposes absorption during the DPN rehydration, thus returning a 
moderate EE of ∼ 3. The beneficial effect of identifying the right 
hydrophobicity/hydrophilicity ratio is presented by the DOX case. LA-DOX is significantly 
hydrophobic with a LogP of 6.59. This leads to an EE of ∼ 7, which, incidentally, is higher 
than that obtained for the more hydrophobic DSPE-MTX. Notably, DSPE-DOX has a LogP 
of - 14.42 returning an EE of ∼ 40%. Figure 11D also shows how direct loading, in the 
current configuration, is far less efficient than absorption loading. This data confirms that the 
hydrophobicity/hydrophilicity ratio and molecular weight of the prodrug are critical features 




Figure 11 Optimization of Absorption Loading and Ecanpsulation Efficiency into Discoidal Polymeric Nanoconstructs. 
Variation of the encapsulation efficiency and DPN size and z-potential with A. the rehydration time; B. the pro-drug mass; 
and C. the volume of the rehydration solution. D. Encapsulation efficiencies for the six different pro-drugs and two different 




2.7. Release profile of prodrugs from DPNs 
Release studies were conducted for all loaded prodrugs under the sink condition by exposing 
a known amount of DPNs to a 4 L aqueous solution. Starting with DSPE-Cy5-A (Figure 
12A), an initial huge burst was observed over the first 10h with 70% and 60% of the agent 
released for the absorption and direct methods, respectively. At 72h, the DSPE-Cy5-A loaded 
via the absorption method was fully released out of DPNs as compared to a 90% release for 
the direct method. Indeed, the DSPE-Cy5-A suffers of a high water solubility, which would 
justify the observed rapid release profile. Moreover, in the absorption method, most of the 
DSPE-Cy5-A molecules are likely trapped near the DPN surface, which indeed facilitates 
their release in the surrounding aqueous environment. On the other hand, the direct loading of 
DSPE-Cy5-A favors its uniform distribution within the DPN polymeric matrix, thus slowing 
the release rate. A different behavior is observed for the more hydrophobic compound DSPE-
Cy5-B (Figure 12B). Over the first 10h, only 35% and 12% of the loaded DSPE-Cy5-B are 
released out of DPNs for the absorption and direct methods, respectively. At 72h, these two 
values become 60% and 35%, respectively. The slower release of DSPE Cy5-B as compared 
to DSPE Cy5-A should be ascribed entirely to the different hydrophobic/hydrophilic ratio, 
which is in favor of the Cy5-B compound. Notably, the direct method is still characterized by 
a lower release rate, possibly because of the uniform distribution of the compound within the 
DPN polymer matrix. The release profiles for DSPE-MTX and PEG-MTX are presented in 
Figure 12C and Figure 12D, respectively. A different behavior is observed as compared to 
DSPE-Cy5 due to the different hydrophobicity. The release of DSPE-MTX was characterized 
by an initial burst over the first 6h with 50% of the drug being released for both loading 
methods. Interestingly, the release of DSPE-MTX was observed to plateau around 60% at 
about 24h. A similar observation applies for PEG-MTX but only for the direct method 
loading. For the absorption loaded PEG-MTX, the compound leaked out of the DPN matrix in 
a sustained fashion over the whole period of observation. Note that DSPE-MTX is the most 
hydrophobic compound realized in this work and, as such, prefers to stay associated within 
the PLGA/PEG matrix. This would explain the plateau observed in Figure 12C. Interestingly, 
the value of the plateau is similar for both direct loaded DSPE-MTX and 1kDa PEG-MTX, 
thus confirming the role of compound hydrophobicity. On the other hand, the absorption 
loaded 1kDa PEG-MTX, which is mostly confined to the DPN surface given its significant 




Figure 12 .  Release profiles of the prodrugs from DPNs. Release profiles for A. DSPE-CY5-A; B. DSPE-CY5-B; C. DSPE-
MTX; D. PEG-MTX ; E. LA-DOX; and F. DSPE-DOX, which have been loaded via the “direct method” (•) and the 
“absorption method” (▪). 
 
 The LA-DOX release is documented in Figure 12E. The release profiles for the direct and 
absorption loaded compound are quite similar to a moderate burst release within the first 24h. 
Indeed, this initial burst was lower than for the MTX as, over the first 10 hours, 55% and 50% 
of the LA-DOX was released via the absorption method and direct method, respectively. 
Then, a total of 70% and 65% DA-LOX was released at 24 hours, respectively. The DSPE-
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DOX (Figure 12F) was only loaded through the abortion method, given its hydrophilicity. 
After the first hour, 80% of DSPE-DOX was already released out of DPNs. Note that DSPE-
DOX is more soluble in water than DA-LOX, and this would explain the faster release rates 
documented for the first compound as compare to the second compound. This data confirms 
that the hydrophobicity/hydrophilicity ratio and molecular weight of the prodrug play a 
critical role also in optimizing the release profiles. 
 
2.8.  Cell viability studies for the DPNs and related prodrugs 
Using the MTT cell proliferation assay, the cytotoxicity of DPN and its prodrugs were tested 
on MDA-MB-231 breast cancer cells at 24, 48, 72 and 96 hours. Free MTX and PEG-MTX 
manifested a modest cytotoxicity potential, which is in line with the existing literature. On the 
other hand, DSPE-MTX presented a much lower IC50 following in the verge of a few tens 
and a few μMolar concentrations, from 24 to 72h of incubation (Supplementary Figure 10A-
C). However, the moderately low cytotoxicity associated with the low encapsulation efficacy 
returns an insufficiently high cell killing activity for the MTX loaded DPNs (Supplementary 
Figure 10D). Consequently, the cell viability analysis focused on the DOX prodrugs. In 
general, the LA-DOX prodrug treatments were associated with a delayed response as 
compared to free DOX. Specifically, at 24h, the IC50 decreased from 17.8 μM of free DOX 
to 34.01 μM of LA-DOX (Figure 13A-C). This trend was documented for all tested 
conditions and it should be ascribed to the hydrolyzation of the amide bond between DOX 
and oleic acid, which indeed require times. Importantly, the loading of LA-DOX into DPNs 
did not further reduce the cell-killing potential. Only at 24h, the IC50 values associated with 
LA-DOX DPNs were higher than for free LA-DOX (Figure 13C). As per DSPE-DOX, the 
loss in activity was even higher. At 24h, the IC50 decreased from 17.8 μM for free DOX to 
196 μM for DSPE-DOX (Figure 13C). Even at 96h, there was a reduction in IC50 of about 50 
times as compared to DOX and 5 times as compared to LA-DOX. However, the IC50 values 
for the DSPE-DOX and LA-DOX loaded DPNs were documented to be quite similar at 48, 72 
and 96h of incubation (Figure 13C). 
In order to characterize the drug uptake by the breast cancer cells, MDA-MB-231 were 
incubated with free DOX, prodrugs (DSPE-DOX and LA-DOX) and DPNs loaded with the 
prodrugs for 24, 48, 72 and 96h. Representative confocal fluorescent images are provided in 
Figure 13B). Both free DOX and free LA-DOX were observed to rapidly enter the cell and 
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distribute within the cytosol around the cell nuclei. This process was also observed for the 
DSPE-DOX and the DPNs loaded with DSPE-DOX and LA-DOX. However, in these latter 
three cases, cell internalization was significantly delayed in time because of the lower 
efficiency of DSPE-DOX in entering the cell, as compared to DOX and LA-DOX, and the 




Figure 13.  Cytotoxic activity of DOX prodrugs and DOX-loaded DPNs. A. Cell viability analysis of free-DOX, DSPE-DOX, 
DSPE-DOX DPNs and LA-DOX at 24, 48, 72 and 96h of incubation on triple negative breast cancer cells (MDA-MB-231). 
B. Representative confocal microscopy images of free-DOX, DSPE-DOX, DSPE-DOX DPNs and LA-DOX in MDA-MB-231 
at 96h. C. Summarizing table listing the IC50 values for free-DOC, DSPE-DOX, DSPE-DOX DPNs and LA-DOX onto MDA-




2.9. Pre-clinical biodistribution studies for the DPNs 
DPNs directly loaded with DSPE-Cy5-B were administered into black mice via the tail vein 
injection. The accumulation of DSPE-Cy5-B DPNs in the different organs was assessed 
longitudinally by using a 
whole animal, near infra-red fluorescent (NIRF) imaging system(Figure 14A). Representative 
images were taken at 0.5, 1, 2, 6, 24, and 48h post tail vein injection. Also, at 48h, the major 
organs such as the liver, spleen, kidneys, heart, lungs and brain, were harvested and imaged 
ex-vivo (Figure 14B). Given the absence of tumor mass or any other diseased tissues, DPNs 
were observed to accumulate within the abdominal cavity over time (Figure 14A). The lack of 
fluorescence signal in the bladder during the experimental observations would confirm a not 
significant leakage of DSPE-Cy5-B from DPNs during circulation. However, it should be 
highlighted that a moderate reduction in the Cy5 signal is observed in the abdominal cavity 
(Figure 14A), which would suggest a modest but sustained release of Cy5 from DPNs in 
agreement with the release studies of Figure 12B for the directly loaded molecule. The insets 
of Figure 14B confirm that the DPN accumulation in the liver. Indeed, this was expected 




Figure 14.  Polymeric Nanoconstructs Biodistribution at 30 min, 1h, 2h, 6h, 24 and 48 h Post Injection. Representative ex 
vivo fluorescence images of the harvested liver (L), spleen (S), kidneys (K), intestine (I), heart (H), lungs (LU) and brain (B) 











Although a variety of compositions and formulations of materials have been tested for 
nanomedicines, the design paradigm has not changed and is still mostly based on the EPR 
effect. the majority of nanoparticles described in the open litterature are spherical with an 
average diameter ranging from tens to a few hundred nanometers. They are the simplest to 
realize and given the size, they seem easily reach the target. However, following the 
biological inspiration, deformable non-spherycal nanoparticles with a characteristic 
submicrometric or even micrometric sizehave been shown to resist the sequestration of 
professional phagocytic cells, circulate for long time and efficiently deposit within the 
tortuous tumor microvasculature. Furthermore, model-based microfabrication strategies allow 
the development of polymeric nanoconstructures whose dimensions, shape, surface 
properties, mechanical rigidity and useful loads can be systematically and independently 
modified during the synthesis process. This supports the creation of a broad spectrum of 
polymeric nanoconstructs. One goal addressed in this work was the creation of a simple, 
reproducible, quick and efficient method for DPNs production with an enhanced yielding.  In 
order to scale up the DPNs production, this study was first dedicated to the microfabrication 
process optimization.  The first step of the fabrication, modified silicon-template approach 
through the use laser writer and electron beam lithography, allows us to control 2 of the 4S 
parameters (Size and Shape). The analysis was specifically focused on: the pattern design 
step; the defocus and dose parameter on the laser writing step; and the PDMS replica molding 
step. The pattern with nanometric structures has been reproduce on large areas, dozens of 
centimeters, leading to the production of an high number of particles (billions) in just a few 
hours.   The conditions necessary to produce four different Nanoconstructs configurations 
(1µm circular shape, 2µm circular shape, elliptical and squared shape)  were set up with the 
intent to study their in vitro and in vivo different behaviors.  
Besides, this work involves for the first time the use of the DLW lithographic technique to 
fabricate a silicon master template presenting a so large array with structures in the limits of 
resolution.  
Changes in polymer amount led to the creation of DPNs with different mechanical stiffness 
(s-DPNs, r-DPNs and rr-DPNs). These particles were used to dissect the influence of 
mechanical stiffness together with size and shape on macrophage nanoparticles 
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internalization. An atomic force microscopy analysis under wet conditions was performed to 
determine the morphological and mechanical properties of DPNs. 
Moreover, the geometrical properties of all DPN configurations were plenty characterized 
using multiple, different techniques including confocal fluorescent microscopy, transmission 
electron microscopy, multisizer coulter counting, and dynamic light scattering.  
Two different loading strategies were documented to encapsulate hydrophobic and 
hydrophilic imaging and therapeutic compounds within the polymeric matrix of the Discoidal 
Polymeric Nanoconstructs (DPNs). Two near-infra red imaging molecules were considered, 
namely Cy5A and Cy5B, together with two therapeutic molecules, methotrexate (MTX) and 
doxorubicin (DOX). The hydrophobicity/hydrophilicity ratio and molecular weight of these 
molecules were modulated by conjugating them directly with lipid (DSPE) and polymeric 
chains (PEG 1kDa). In the straightforward “direct loading” method, the compounds were first 
dissolved in the polymeric paste forming the DPNs and then, together with this paste, applied 
to the PVA template. This approach suffered of the current sub-optimal fabrication yielding of 
DPNs returning encapsulation efficiencies lower than 1%. In the “absorption method”, the 
compounds were resuspended in water at high concentrations (1 mg/ml) and dragged inside 
the polymeric matrix of DPNs upon their rehydration. This approach required a fine tuning 
between the compound hydrophobicity and molecular weight and returned encapsulation 
efficiencies as high as 80%. In addition, direct loading was associated with lower release rates 
as compared to absorption loading, for a given compound. This was ascribed to the fact that 
the compounds in the absorption loading are mostly confined in the vicinity of the DPN 
surface and are therefore more rapidly released into the surrounding aqueous environment. 
Differently, in direct loading, the compounds are uniformly distributed within the polymeric 
matrix. 
Collectively, these results demonstrate that the pharmacological properties of DPNs can be 
finely tuned during the fabrication process by changing the loading strategies (direct vs 
absorption) and compound properties (hydrophobicity and molecular weight). Future studies 
will focus more on further optimizing the loading and release conditions and pre-clinically 
demonstrate the therapeutic and imaging performance of this drug delivery platform in 
different disease models.  
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Finally, the DPN fabrication process can be integrated with roll-to-roll and roll-to-plate 





















3. Chapter: Mechanical-control of chemotherapeutic drug efficacy 
The goal of this part of my PhD is to investigate the impact of mechanical stress on drug 
efficacy. We studied different mechanical perturbations that may contribute to a mechanical-
form of drug resistance. We investigated different types of mechanical stresses: mechanical 
compression (3D level), osmotic stress (3D level) and rigidity (2D level). Compressive stress 
is the least studied of mechanical stresses. To achieve these goals, we developed a new 
experimental strategy to exert a well-defined mechanical stress on multicellular tumor 
spheroids for over 20 days. Essentially, we used two strategies to apply mechanical 
compressive stress at the 3D level: dextran osmotic stress and agarose confinement. We then 
tested the drug efficacy of common pancreatic cancer chemotherapeutics, Gemcitabine and 
docetaxel. The basic growth curves that we had display d(t)/d0, the spheroid diameter d(t) 
normalized by the initial diameter of the spheroid d0. Since the geometry is spherical, 
diameter measurement gives as much information as volume measurement. 
3.1. Context  
 
3.1.1. Cancer progression: role of mechanical stress  
 
Cancer progression occurs in several phases: schematically, the tumor grows locally, then 
typically invades the nearby tissue called stroma composed of extracellular matrix, 
fibroblasts, immune cells and capillaries. Proliferation during the early stages of the tumor is 
controlled by three macro-elements: gene mutations, biochemical and mechanical parameters 
imposed by the micro-environment. Biochemical and mechanical factors are difficult to 
isolate in vivo to measure their respective importance. The idea that mechanical stresses in 
tumor development can play a key role is increasingly supported (98) (99) (100) (101) (102) 
(103).  In most solid tumors, the growth occurring in constrained environments entails a 
competition for space and this requires that cells physically push onto their surrounding 
environment and to create space to be able to divide (fig. 15a). This is a physical force that 
cells exert on their microenvironment. The competition for space results in a mechanical 
coupling between the tumor and the stroma: the expanding neoplastic tissue compresses the 
stroma which accumulates and stores an internal stress. Moreover, stromal elements can 
participate in mechanical stress build up. For instance, myofibrobalasts, the contractile 
component of the stroma, as well as high deposition of hyaluronan can exert mechanical 




Figure 15. Mechanical compressive stress accumulating during tumor growth. (a) In most solid tumors the growth 
occurring in constrained environments entails a competition for space ; (b) the neoplastic cells physically push their 
surrounding environment and the stroma accumulates and thus stores an internal stress (this pressure could lead vessels 
collapse). 
 
It has been shown that mechanical stress leads to a reduction of tumor cell proliferation (105) 
(106) (107) (108) and induces mitochondrial apoptosis (cellular suicide) (5) (109) (110). 
Despite these experimental evidences, the role of the microenvironment and its interactions 
with the tumor is not yet clear (13).  Probably, a quantitative analysis is difficult because large 
tumors are polyclonal, their shapes are often poorly defined, they are heterogeneous and 
biochemical signaling interferes with mechanics (111) (112). However, a quantitative 
knowledge of the mechanical properties of tissues is of paramount importance for 
understanding tissue growth and invasion. 
 
3.1.1.1. Tensile and compressive mechanical stresses 
 
Mechanical stresses can be divided into two main groups: tensile and compressive stresses. 
Tension naturally emerges from cell–cell and cell–substrate adhesion, and has been shown to 
affect cell proliferation, cell death, cell migration, and even cell differentiation (113) (114) 
(115) (116) (117). Mechanical compressive stresses arise in a spatially limited environment 
and can also modulate cell division and migration (105) (106) (118). For instance, tumor 
multicellular aggregates growth can be inhibited when embedded in an elastic agarose gel 
(110). In particular, the stiffer the agarose gel, the stronger the inhibition. Agarose gels are 
deformed by the growing aggregate. As a consequence, they mechanically react by applying 
an increasing stress to the spheroid. Above a certain stress, spheroid growth stalls. 
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Tensile stresses have been extensively studied and much is known about their molecular 
integration (119). On the contrary, relatively little is known about the molecular determinants 
responding during mechanical compression. Tensile stresses mostly concern cells of the outer 
layer of the tissue that interact with the external microenvironment through adhesive proteins, 
instead the compressive stresses, even if in different ways, affect any cell into the tissue. 
Despite these qualitative observations, the precise mechanisms linking mechanical forces to 
tumorigenesis remain unknown. One reason why progress in understanding the role of 
mechanical stress did not follow the pace of biochemical studies is the lack of adequate tools 
to measure in vivo or in vitro forces in 3D culture models. The cells constantly receive various 
physical forces associated with the tissues, including hydrostatic pressure, shear stress, solid 
compression and tension, and among these we are able to precisely measure only a few. 
Moreover, dissociating the combined effect of these stresses is important to assess them 
properly. 
3.1.2. Mechanical forms of drug resistance  
 
What are the mechanisms of drug resistance? Many past studies have identified key features 
which can eventually lead to drug resistance. Most studies have focused on the very 
inactivation of the drug by the host, the alteration of the drug target, the efflux of the drug 
from the cell, or DNA alterations that could create de novo resistance (120). All of these 
mechanisms are cell-centered, but there is an increasing realization that stromal components 
could also participate in the mechanisms of drug resistance. Incidentally, the lack of stromal 
components when investigating new therapeutic targets could explain the large fraction of 
drugs failing clinical trials.   
As we mentioned above, cancer cells constantly interact with their mechanical environment 
and the whole tissue is confined and compressed by its surrounding. Compressive mechanical 
stress develops from cell proliferation and finally, the elevated mechanical stress could result 
in the clamping of blood vessels leading to increased interstitial fluid pressure (hydrostatic 
pressure) (Figure 15b). The consequent hypoperfusion and interstitial hypertension pose 
important obstacles to drug delivery and may exclude large intratumor areas from therapeutic 
agents of blood origin, which could lead to reduced efficacy of chemotherapy (8) (9). In this 
case the mechanical stress creates a real physical impediment to the drug to reach the tumor 
site or part of it (121). It is quite obvious to imagine that if the drug fails to reach the tumor it 
cannot work on it. However, what happens from compressed tumors with sufficient 
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perfusion? Such situation could arise for mechanical stress not high enough to collapse blood 
vessels, but large enough to have a physiological effect on tumor cells.  
While some recent studies show that mechanical stresses, tensile (122) (123) (124) 
compressive (104) (125), or shear (125) (126) (127) are associated with drug resistance, the 
mechanisms leading to such resistance are still elusive. Most of the drugs tested and current 
chemotherapeutic strategies require cells to proliferate in order to work: for instance, 
Gemcitabine is a DNA incorporating agent promoting irreversible error during DNA 
replication leading to cell death, and docetaxel prevents normal breakdown of microtubules 
during division, also leading to cell death. Consequently, if a cell does not proliferate, these 
drugs would not work. We and others have shown that tensile or compressive have been 
linked to a cell cycle arrest (106) (128), which can be a potential additional form of drug 
resistance. The idea that quiescence can be a dominant mechanism leading to drug resistance 
is appreciated (129), but its relationship with mechanical stress has not yet been demonstrated.  
Although remaining an underexplored axis of research, the mechanisms coupling drug 
resistance to mechanical stress could bridge the gap between the cell-oriented research and the 
impact of the mechanical environment, which could both inform on approaches to better 
delineate chemotherapeutic strategies and design new high-throughput screening platforms. 
We propose that mechanical perturbations of the tumor microenvironment may contribute 
substantially to the mechanism of Gemcitabine drug resistance. 
3.1.3. Gemcitabine: metabolism and molecular mechanism of action to treat pancreatic 
cancer. 
 
Gemcitabine is a nucleoside analog that has been used as a chemotherapeutic agent for more 
than 15 years (130). Proliferating cells are the target of Gemcitabine where it replaces cytidine 
during DNA replication. This process decrease tumor size, as new nucleosides cannot be 
attached to the "faulty" nucleoside, resulting in apoptosis. 
Gemcitabine has become the standard treatment choice for locally advanced and metastatic 
pancreatic cancer, for which there have been few treatment advances.  
Gemcitabine (2’,2’-difluoro-2’-deoxycytidine) is a deoxycytidine analog with multiple modes 
of action inside the cell (figure 16a). The basics of Gemcitabine metabolism is illustrated in 
Fig. 16b. Gemcitabine is a prodrug that requires cellular uptake and intracellular 




Figure 16. (a) (2’,2’-difluoro-2’-deoxycytidine ; (b) Gemcitabine metabolism and mechanism of action (133). 
 
Once administered, Gemcitabine is transported into cells by nucleoside transporters. 
Gemcitabine is then phosphorylated into Gemcitabine monophosphate (dFdCMP) by 
deoxycytidine kinase (DCK), and dFdCMP is subsequently phosphorylated to Gemcitabine 
diphosphate (dFdCDP) and Gemcitabine triphosphate (dFdCTP) by nucleoside 
monophosphate (UMP/CMP) and diphosphate kinase. The most important mechanism of 
action of Gemcitabine is inhibition of DNA synthesis (134). When dFdCTP is incorporated 
into DNA, a single deoxynucleotide is incorporated afterwards, preventing chain elongation 
(135). This non-terminal position of Gemcitabine makes DNA polymerases unable to 
proceed, in a process known as ‘masked chain termination’, which also inhibits removal of 
Gemcitabine by DNA repair enzymes (134). Moreover, it is known that Gemcitabine has a 
unique mechanism of action known as ‘self-potentiation’ (136). For example, dFdCDP 
potently inhibits ribonucleotide reductase, resulting in a decrease of competing 
deoxyribonucleotide pools necessary for DNA synthesis. Again, dFdCTP suppresses 
inactivation of dFdCMP by inhibiting deoxycytidine monophosphate deaminase (DCTD). On 
the other hand, more than 90% of administered Gemcitabine is converted, and thus 
inactivated, by cytidine deaminase (CDA) into 2′-deoxy-2′,2′-difluorouridine (dFdU). 
Phosphorylated metabolites of Gemcitabine are reduced by cellular 5′-nucleotidase (5′-NT), 




Like many other drugs used in cancer chemotherapy, resistance to Gemcitabine may be 
intrinsic, but it can also be acquired by individual patient during treatment cycles. Several 
mechanisms have been reported in the literature; however, as many of these processes are 
complex, it can be difficult to understand the precise roles and, indeed, consequences in 
chemoresistance. Anyway the only strong correlations with gemcitabine sensitivity are DCK 
activity and dFdCTP pools, with a potential important role for ribonucleotide reductase. These 
mechanisms have been extensively reviewed (137) (138) (139).  
It is not known exactly why Gemcitabine is active against pancreatic cancer while other 
chemotherapeutic agents are not. However, the tumor environment is thought to be important. 
This malignancy is characterized by deficient vascularization and dense stroma, which is 
therefore difficult to penetrate by many drugs as well as the immune system. In fact, among 
all epithelial tumors, pancreatic cancer is known to possess an extensive desmoplastic 
reaction, which may account up to 90% of the tumor volume (140). Thus, desmoplastic results 
in poor drug delivery and intrinsic chemoresistance. 
The introduction of Gemcitabine triggered several exploratory studies of its combination with 
other therapeutic agents. In particular Gemcitabine and Docetaxel were combined into 
advanced pancreatic cancers (Phase II or III) as second line therapy (141) (142) (143) (144). 
From these studies came out that Gemcitabine and docetaxel had encouraging activity in 
patients with advanced pancreatic cancer. 
3.1.4. Pancreatic cancer as a model cancer to study a mechanical-form of resistance 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human neoplasms with 
extremely poor prognosis when diagnosed and no efficient treatment available (145). PDAC 
development is characterized by excessive deposition of extracellular material during which 
strong modifications of the mechanical environment arises. In particular, the deposition of 
negatively-charged hyaluronic acid leads to electroswelling of extracellular matrix and 
subsequent compressive stress experienced by tumor cells (146). The local growth of cancer 
cells in an elastic environment also leads to build-up of solid stress through a process known 
as growth-induced pressure (3) (147).  Pain in the abdomen or back is common in pancreatic 
cancer. Pancreatic tumors can grow large enough and quickly begin to feel the pressure of 




These physical forces could compress the blood vessels causing poor and heterogeneous 
tumor perfusion. Moreover, these mechanically-induced changes could create a barrier to the 
delivery and efficacy of chemotherapeutics (150).  
In fact, the rapid clinical decline commonly observed in patients with pancreatic cancer has 
been attributed both to the aggressive biological nature of PDAC and to the ineffectiveness of 
systemic therapies available for patients with advanced disease (151) (152). After surgical 
resection of PDAC, the nucleoside analogue Gemcitabine has been widely used for many 
years as standard treatment based on the results of the European Study Group study for 
Pancreatic Cancer-3 (ESPAC-3) (153). Over the years many combination therapies of 
Gemcitabine and other drugs have been introduced (141)  (154), in particular Gemcitabine 
with nab-paclitaxel has been shown to have a beneficial effect on patient survival (155). 
Although these chemotherapeutic drugs gave a great improvement in pancreatic cancer, the 
median survival rate remained small (145). An explanation for the poor response of patients to 
systemic therapies was provided in an accurate PDAC mouse model from the demonstration 
that chemotherapy is poorly delivered to PDAC tissues due to a lack of vascularization (156). 
This vascular deficiency was related to the presence of the dense stromal matrix which 
constitutes the mass of tumors of the PDAC (figure 17). The stromal cells contained in the 
PDAC tumor microenvironment are therefore an additional component of neoplastic cells that 
should be critically evaluated for optimal therapeutic development.  
 
Figure 17.  Stain of human pancreatic ductal adenocarcinoma showing a prominent desmoplastic reaction (black arrows) 




In the past, the stroma was considered as a spectator during pancreatic carcinogenesis. 
Pancreatic cancer was understood as a multistage process characterized by the accumulation 
of genetic alterations accompanied by typical morphological and histological changes in 
pancreatic ductal cells. Activating mutations in the Kras oncogene occur early during 
malignant transformation, followed by subsequent somatic mutations involving the tumor 
suppressor genes p16, p53 and DPC4 (157) (158).  Classical molecular biology concepts are 
increasingly replaced by complex multidisciplinary approaches that address stromal 
determinants and their interplay in PDAC. Based on recent sequencing studies and 
transcriptional profiling analyses on PDAC, it is acknowledged that the tumor 
microenvironment plays a pivotal role during pancreatic carcinogenesis and therapeutic 
resistance (140) (159).  
Pancreatic cancer is characterized by a pronounced desmoplastic and hypovascular 
microenvironment. The development of fibrosis is a dynamic phenomenon where ECM 
formation takes place in the interstitial spaces and in areas where the exocrine compartment, 
mainly acinar cells, is damaged (160). PDAC stroma consists of activated fibroblasts, 
Pancreatic stellate cells, infiltrating immune cells, all cells produce key molecules during 
fibrosis collagen types I, IV, and V, and fibronectin, laminin, matrix metalloproteases 
(MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), and TGFβ. 
Since in the last years, different studies have concluded that the tumor stroma modifications 
promote PDAC progression and mediate therapeutic resistance, strategies have been setup in 
order to target tumor stroma components and pathways. In particular, the targeting of the 
stromal cells results in an increased intratumoral perfusion and therapeutic delivery of 
Gemcitabine if used in combination with drug targeting ECM rigidity (156). However, these 
studies were mostly done in vitro or in transplanted immune deficient in vivo models, without 
taking into consideration the real complexity of pancreatic cancer microenvironment. Indeed, 
clinical trials with the matrix metalloproteases inhibitors marimastat/BAY1295-66 failed. The 
disappointing clinical outcome of these and others studies based on increase drug delivery 
strategy led to the understanding that the role of the stroma as PDAC promoting or suppressor 
is dependent on tumor stage, tissue context and others microenvironment component (159). 
This is supported by interesting works showing that in different genetic engineered mouse 
models (GEMMs), the depletion of carcinoma associated fibroblasts, which are a driver for 
desmoplastic stroma formation, accelerates pancreatic cancer (161). Interestingly one 
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effective approach in clinic to address the stroma seems to target non-cellular components. 
Preclinical studies in GEMMs demonstrate that the drug PEGPH20, a recombinant 
hyalurodinase able to degrade hyaluronic acid (HA), induce an increased tumor blood vessels 
perfusion and delivery of chemotherapeutic agents (162).  
Even though drug resistance stemming from mechanical stress may be general to any cancer, 
we propose to investigate the role of mechanical stress on pancreatic ductal adenocarcinoma 
(PDAC). This cancer, as we explained above, presents strong modifications of stromal 
components, a higher matrix rigidity and a subsequent abnormal solid stress in comparison to 
healthy tissue which contribute to cancer progression and resistance to current treatments, 
making it a perfect candidate to study the impact of compressive stress. How mechanical 
stress affects PDAC development and treatment remains elusive. Note that in this study we 
decided to not consider the potential drug resistance due to hypoperfusion of tumor tissues 
under mechanical compression. 
We propose that mechanical perturbations of the tumor microenvironment may contribute 
substantially to the mechanism of drug resistance. 
 
3.2. Focus of the work 
 
The goal of this work is to understand the impact of mechanical stress on drug efficacy. We 
tested the mechanical stress on pancreatic cancer progression in vitro, and in that context, the 
efficacy of Gemcitabine chemotherapy. We measure the effect of a compressive mechanical 
stress on the growth of multicellular spheroids over time scales longer than the typical time 
scales of cell division or apoptosis. A good candidate for such studies is the multicellular 
spheroid (MCS), introduced by Sutherland et al. (163) as a tumor model system: three-
dimensional cellular aggregates that remarkably mimic the relevant in vivo physiological 
gradients of mitogens, oxygen, or glucose. They have been extensively used as model system 
for the study of drug delivery, cell proliferation or even angiogenesis (164). Although their 
mechanical properties may differ from those of tumors, for many purposes, MCS can be seen 
as a tumor subunit. Since they have no biochemical crosstalk with their environment, MCS 
are ideal for assessing the impact of mechanical stress on tumor growth (165) (166). We 
prepare PDAC cell spheroids derived from mouse A338 K-Ras
G12D 




Growth of a tumor occurs through an abnormal proliferation program of cells (167) (168), 
which as a consequence induce growth-induced compressive stress accumulation at the 
tumor–stroma interface. In order to study the spheroid growth response to compressive 
mechanical stress we use an agarose gel as a highly simplified stroma. Several groups have 
been seeding gels with cell aggregates (110) (166) (5) (6): during growth, the cell aggregate 
has to distort the gel resulting in an elastic stress (figure 18). The stiffer the gel, the smaller 
the growth rate of the aggregate and its final size at steady state. In other hands, tumor 
multicellular aggregates growth can be inhibited when embedded in an elastic agarose gel 
(110). In this work we use a new experimental strategy to exert a physical mechanical 
compressive stress onto the whole multicellular tumor spheroid for a period of time which can 
exceed 20 days (figure 18).  
 
Figure 18. (Left) free and agarose embedding spheroids growth scheme: because the spheroid growth (arrows to outside) 
the agarose mechanically reacts by applying an increasing stress to the spheroid (arrods to  inside) ; (Right) Free and 
embedded spheroids size evolution. 
 
Subsequently, we tried to make consistent the the tumor growth mechanical stress 
dependence, testing other mechanical stresses. For this purpose we used a high molecular 
weight Dextran to induce an osmotic compressive stress on the spheroid. The dextran has 
been shown in previous works to reduce the growth of colon carcinoma cell spheroids (169) 
(170) (105) (106).  This polymer is known to be neutral and is not metabolized by mammalian 
cells (169).  Unlike more physiological osmolytes, such as glucose or ions (Na+, Mg2+, etc), 
dextran macromolecules are not internalized by cells, and do not infiltrate the intercellular. 
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Thus, they exert a constant osmotic stress onto the whole spheroid and induce a water efflux 
from the spheroid (171) (107), probably from the matrix components (172). Moreover, it has 
been observed that such a small osmotic pressure has no long term effect on proliferation or 
death for cells cultured in 2D (107). We used a stress of 0.5 kPa, 1kPa and 2kPa and it is 
worth noticing that even 5 kPa is a rather small stress corresponding to the osmotic pressure 
exerted by 1 mM NaCl (107). We investigated the similarities between agarose mechanical 
and dextran osmotic stresses.  
Cancer cells due to their growth in a rigidity-changing environment are subjected to a tensile 
stress mediated by the substrate stiffness. The stiffness and the geometry of the substrate on 
which cells grow have indeed a strong impact on cell division (173), migration (174) and 
differentiation (175). Starting from these considerations we wanted to confirm further our 
hypothesis of tumor progression in dependence on mechanical stress. We investigated the role 
of substrate stiffness as a source of mechanical stress: we performed a 2D-experiment with 2 
specific rigidity plates with Young moduli of 0.5 kPa and 64 kPa. 
Once we saw a reduction in growth as a function of different mechanical stress, we wondered 
whether that meant even reduction of cell division and proliferation. Therefore, we performed 
an ad hoc capillary Western blot analysis and, when we could, immunostaining of sections.  
Once we understood which was the stress-mediated proliferation within the compressed 
spheroids we investigated what was the efficacy of a proliferation-based chemotherapy. We 
evaluated the growth evolution of spheroids treated with Gemcitabine under progressive 












3.3.1. Cell line and 3D culture 
Pancreatic ductal adenocarcinoma (PDAC) cell line model was used in this work because of 
the strong modifications of the mechanical environment during progression of this cancer 
(104). For this study, we used immortalized PDAC murine cell lines: a constitutively active 
Kras
G12D
 mutant (oncogene mutated in 95% of pancreatic cancer (176)), A338. Kras mutation 
is present in 95% of cases and is a gene involved in proliferation and invasion pathways 
(176).  Our collaborators in the group of Julie Guillermet-Guibert (CRCT - Centre de 
Recherche en Cancérologie de Toulouse) derived this cell line from mice pancreatic cancer 
lesions. The cells were cultured with Dulbecco's Modified Eagle Medium (DMEM) 
containing 10% FBS (Gibco, Thermo Fisher Scientific, USA), 1% penicillin/streptomycin 
(Sigma-Aldrich, USA), under a controled atmosphere (37°C, 5% CO2, 95% air).  
Given the complexity of the tumor systems, uncoupling the effect of biochemical and 
mechanical interactions is a daunting challenge. A good candidate for such studies is the 
multicellular spheroid (MCS) as a tumor model system: three-dimensional cellular aggregates 
which remarkably mimic the relevant in vivo physiological gradients of mitogens, oxygen, or 
glucose (163). They have been extensively used as tumor model systems (164) for the study 
of drug delivery (177), and three-dimensional cell proliferation (178). Although their 
mechanical properties might differ from those of tumors, for many purposes, MCSs can be 
viewed as a tumor subunit. Because they do not have any biochemical crosstalk with their 
environment, MCSs are ideal to evaluate the impact of mechanical stress on tumor growth 
(165) (166). 
We make spheroids using a classical agarose cushion protocol (179) : an agarose pad of 200 
µl of agarose 2% is prepared first into a well of a 48 multiwell plate, then 600 µl of 1800 
cells/ml suspension are placed on the agarose pad and the spheroid is formed (figure 19a). 
The  the spheroid is formed in the center of the well following the curvature of the agarose in 
less than 24h (169) (170) (106) (fig. 19a). 
 
3.3.2. Chemotherapeutic drugs  
Gemcitabine, Docetaxel and the smart drug SPNs–Docetaxel were used against the pancreatic 
cancer spheroid progression.  
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Gemcitabine is a nucleoside analog used as chemotherapy. The drug replaces cytidine during 
DNA replication of S-phase cells creating an irreversible error. The process arrests tumor 
growth, as new nucleosides cannot be bound to the "faulty" nucleoside, resulting in apoptosis. 
Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, 
bladder cancer and breast cancer (130). When 10μM of Gemcitabine is added to pancreatic 
cancer spheroids, we observed a progressive decrease of its volume over time, until all the 
cells eventually die out at a 10 μM concentration. 
Docetaxel is of the chemotherapy drug class; taxane, is a chemotherapy medication used to 
treat a number of types of cancer. This includes breast cancer, stomach cancer, prostate 
cancer, non-small-cell lung cancer and second-line therapy in patients with advanced 
pancreatic cancer (180). The cytotoxic activity of docetaxel is exerted by promoting and 
stabilizing microtubule assembly, while preventing physiological microtubule 
depolymerization / disassembly in the absence of GTP. This leads to a significant decrease in 
free tubulin, and results in inhibition of mitotic cell division preventing further cancer cell 
progeny (181). We used the same drug concentration (10µM) to compare the effect with the 
Gemcitabine. 
Spherical Polymeric Nanoconstructs (SPNs) are ideal for targeting solid tumors via the 
enhanced permeability and retention (EPR) effect (182). Moreover, the SPNs had been 
biologically and chemically characterized in vitro and their in vivo therapeutic and imaging 
efficacy in mouse cancer cells heve been proven (182). This platform consist of a 
hydrophobic poly(lactic- co –glycolic acid) (PLGA) polymeric core stabilized by an external 
monolayer of phospholipids and poly(ethylene glycol) (PEG) chains. The hydrophobic core 
contains docetaxel (DTXL) and fluorophore Lipid-Cy5. The SPNs were made out of the same 
materials as DPNs but were obtained via an emulsion/nanoprecipitation approach (182) 
returning a spherical shape with a diameter of 172.4 ± 0.1 nm (PDI = 0.115 ± 0.03) and ζ = 
−44.6 ± 1.14 mV. The Nanocontructs Docetaxel drug loading were verified by HPLC analysis 
and the Docetaxel concentration used was always 10µM.  
 
3.3.3.  The growth of multicellular spheroid embedded in agarose gel 
To investigate the role of mechanical compression on cell physiology we developed a new 
protocol consisting in embedding multicellular spheroids inside an agarose gel. Rather than 
75 
 
embedding single cells as it was previously performed (110) the whole spheroid was 
embedded, which enables an easier tracking in time. The new embedding method proposed in 
this study is reported in the fig. 19 b.  It essentially consists in mixing a 2/3 days-old spheroid 
with a low melt agarose matrix at 37°C and then induce a fast polymerization of the agarose 
on ice to avoid that the spheroid sediments at the bottom and is not fully embedded in 3D. 
After that the spheroid is allowed to grow under confinement for 2 more days and is then 
treated with the chemotherapeutic drug.  
 
Figure 19.  Experimental agarose embedding and dextran compressive stress schematic protocols. (a) growth of control 
spheroids without mechanical stress : at the day 0 the cells are seated into the well to make spheroid, at the day 4 or 5 in 
one case was added the chemioterapic.  (b) growth of spheroids with agarose embedding compressive stress : at the day 0 
the cells are seated into the well to make spheroid, at the day 2 or 3 the spheroid was embedded into an agarose matrix by 
ice fast polymerization  at the day 4 or 5 in one case was added the chemioterapic - The black arrows rapresent the 
emergency growth induced compressive stress ; (c) growth of spheroids with dextran compressive osmotic stress : at the 
day 0 the cells are seated into the well to make spheroid, at the day 2 or 3 the medium was replaced with medium – dextran 
solution, at the day 4 or 5 in one case was added the chemioterapic – the black arrows  rapresent the osmotic compressive 
stress on the spheroid. 
More precisely, a 48 multiwell plate is placed on ice and in the same time a low melt agarose 
suspension at double-concentration (2X) is prepared. Then, 400 µl of medium is carefully 
removed from the well containing a 2/3 days old spheroid. The remaining 200 µl of medium, 
that should contain the spheroid, is mixed with 2X low-melt agarose matrix. Then, the 
resulting 400 µl of agarose + spheroid + medium is placed in the 48 multiwell plate on ice to 
induce a rapid agarose polymerization and subsequent spheroid embedding in the central 
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position of the well. At this point the spheroid is allowed to grow under confinement in the 
polymeric matrix of agarose and as it grows it develops a growth-induced pressure from 
polymer that confines it. After 2 days 10 µM of drug was added and the spheroid growth was 
followed for several days.  
The agarose concentrations used to induce a growth induced compressive stress are 1% and 
0.5%. Careful rheological measurements on the stresses associated with different agarose 
matrices were performed by collaborators from the ILM lab in Lyon, France to calibrate the 
amount of growth-induced pressure and asses in which condition we can use it. 
3.3.4. Multicellular spheroids growth in osmotic stress Dextran 
A high molecular weight Dextran (Dextran from Leuconostoc spp. 100kDa – Sigma Aldrich) 
was used to compress multicellular spheroids: spheroids were cultured in a medium 
supplemented with dextran polymer (169) (fig 19a and 19c). Dextran macromolecules are not 
internalized by cells, and do not infiltrate the intercellular space of spheroids (169) (105) 
(170) (106). In this protocol, 300 µl of medium is removed from the well containing a 2/3 
days old spheroid and 300 µl of 2X dextran solution is added. As in the previous case, the 
spheroids grow under compressive osmotic stress, and after 2 days the drug is added. The 
concentrations of dextran and the corresponding osmotic stresses have been previously 
calibrated (183) (184). In this work, the dextran osmotic stresses used were 0.5 kPa (12.5 
g/L), 1kPa (20.5 g/L) and 2kPa (32 g/L). 
3.3.5.  Capillary Western Blot  
We investigated how drug and compressive stress could affect cell proliferation. Since the 
traditional western blot does not have sensitivity sufficient to detect the protein quantity 
present in a single spheroid, capillary Western blot on spheroids compressed by dextran were 
performed to reduce the number of spheroids needed.  
At the end of the experiment the spheroids have to be lysed. 400 µL of medium was removed 
from every well, then the spheroids from the same experimental condition were gathered 
together in a Falcon tube, spun down by soft centrifugation (200 g) and washed with cold PBS 
three times (5 minutes each). It is important to remove most of the liquid from the spheroids: 
the excess liquid would risk diluting the lysis buffer in the next steps. At this point, the dried 
samples could be frozen at -80 ° C or lysed directly. A lysis buffer is prepared with 150mM 
NaCl, 50 mM Tris, 1mM EDTA, 1% Triton; 2 mM of Dithiothreitol (DTT), 2mM of NaF 
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(Serine/Threonine phosphatase inhibitor), Sodium Orthovanadate (Tyrosine Phosphatase 
inhibitor) 4mM and a tablet of complete Roche proteases inhibitor cocktail were added just 
before lysing. Spheroids were then incubated on ice with 200 µl of lysis buffer and vortexed 
regularly for 15 minutes. Then, the samples are centrifuged 5 minutes at 9500 g - 4°C and the 
supernatant is transferred to an Eppendorf tube. It is not possible to make a protein dosage 
before the western blot because the protein content of the spheroids is below the detectability 
threshold. 
The machine Automated Western Blot from Protein Simple Company (Wes) and its 
corresponding preparation kits were used for a high performing capillary Western blot.  It is a 
new automatic protein separation and immunodetection based on the application of the 
Protein Simple capillary immunoassay (Wes) method, a gel- and blot-free. In Wes, proteins 
are size separated in capillaries, where they are incubated with primary and (HRP-conjugated) 
secondary antibodies and finally with Luminol/peroxidase. The produced chemiluminescence 
is detected at multiple exposure times and automatically quantified by the Compass software.  
In particular the first step was the preparation of the EZ Standard Pack reagents (3 minitubes): 
DTT (clear tube), Fluorescent 5X Master Mix (Pink tube) and Biotinylated Ladder (clear tube 
with pink pellet). Each minitube foil was pierced with pipette and 40 µL of deionized water 
was added into the DTT tube to make a 400 mM solution, 20 µL of 10X sample buffer 
(Protein Simple company) and 20 µL of prepared DTT solution were added into the 
Fluorescent 5X Master Mix tube, and in the end, 20 µL of deionized water was added into the 
Biotinylated Ladder tube. 
The samples are appropriately diluted with 0.1 X sample buffer. Then, 1 part 5X Fluorescent 
Master Mix with 4 parts diluted lysate in a microcentrifuge tube (final concentration 0.4 
mg/ml for chemiluminescence) was combined producing enough diluted sample volume 
required for assay. The samples were denatured in a specific hot plate at 95°C for 5 minutes. 
ERK (Extracellular signal Regulated Kinase) was used as proliferation marker (185), cyclin 
dependent kinase inhibitor 1B (p27) was used to identify proliferation inhibition (106) and 
cleaved-caspase 3 was used as an apoptosis marker (185). The loading quantity was 
controlled by the total volume of analyzed spheroids. 
Specifically, the antibodies used were: anti-rabbit ERK 1-2, anti-rabbit Phospho-ERK 1-2  
(pERK 1-2) and anti-cleaved-caspase 3 from Cell Signaling Technology, and anti-rabbit p27 
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from Santa Cruz Biotechnology. The antibodies were diluted 1:50 with the antibodies buffer 
(Protein Simple company). The solution volume is chosen based on the samples number to be 
analyzed in the assay. At the last, was prepared the solution luminol-peroxide with the ratio 
1:1, always.  
Protein samples, blocking reagent, washing buffer, primary antibodies, secondary antibodies, 
and chemiluminescent substrate were dispensed into the assay plate according to the 
manufacturer's protocol. Assay plate was then loaded into the instrument, and proteins were 
separated into individual capillaries. Protein separation and detection was performed 
automatically on the individual capillaries. The data were analyzed by Compass software. 
3.3.6. Analyze the Effect of Matrix Stiffness/Rigidity  
We used the CytoSoft® Elastic Modulus Plates in order to study the effect of different rigidity 
on Gemcitabine efficacy. The plates have to be coated with an extracellular matrix protein 
prior cell addition: after several tests (gelatin, collagen, poly-L-lysin), we decided to use 
fibronectin at the concentration 5 µg/mL, the other coating proteins not giving satisfying 
attachment of the cells. Rigidities of 0.5 kPa, 64 kPa and ~70 GPa (glass Young modulus) 
have been tested. 
For the control experiment with the glass, a circular cover-slip was used. The cover-slip was 
first cleaned by Plasma Oxygen and then placed into a 6 multiwell plate and washed with 2 
mL of ethanol for 15 minutes. The ethanol was aspired and replaced with PBS that was used 
to wash other 3 times the glass (5 minutes each). The surface, at this point, was functionalized 
with 3 mL of 5µg/mL fibronectin solution (in PBS) for 2 hours, then washed with PBS two 
times (5 minutes each). 60000 cells (3 mL of 20000 cells/suspension) were seeded into the 
well and after 24 hours the cells are treated with a 10 µM Gemcitabine concentration and 
monitored by Cytonote 6 wells (Iprasense). This is a holographic microscope which enables 
time-lapses at high resolution of 6-well culture plates. 
The same experimental protocol we followed with 0.5 kPa and 64 kPa rigidity plates. 
3.3.7.  Live dead assay 
The LIVE/DEAD assay was used to estimate cell viability of spheroids treated with 
chemotherapeutics under osmotic stress. The LIVE/DEAD assay provides a two-color 
readout: the calcein AM is well retained within live cells, producing a green fluorescence 
(ex/em ~495 nm/~515 nm), while EthD-1 enters cells with damaged membranes and 
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undergoes an enhancement of fluorescence upon binding to nucleic acids, thereby producing a 
bright red fluorescence in dead cells (ex/em ~495 nm/~635 nm). 
20 µL of the supplied 2 mM EthD-1 stock solution (Component B) were added to 10 mL of 
sterile, tissue culture–grade D-PBS, vortexing to ensure thorough mixing. This gives an 
approximately 4 µM EthD-1 solution. Then, the reagents were combined by transferring 5 µL 
of the supplied 4 mM calcein AM stock solution (Component A) to the 10 mL EthD-1 
solution. We vortex the resulting solution to ensure thorough mixing. The resulting 
approximately 2 µM calcein AM and 4 µM EthD-1 working solution is then added directly to 
the spheroids previously washed in PBS three times for 5 minutes each. 
3.3.8. Transparization protocol 
The imaging of 3D cell cultures is highly challenging due to its high thickness, which results 
in a light-scattering phenomenon that limits light penetration. The ability to resolve and 
segment individual cell nuclei in 3D culture models is a necessary prerequisite to distinguish 
different cell subpopulations into the spheroids (186). 
Here we present a protocol for nuclear clearing / transparization in spheroid models.  
Essentially, we first perform the live-dead assay before following the transparization protocol: 
blocking the spheroids into a low-melt 2% agarose matrix and fixing with Paraformaldehyde 
3.7%, permeabilisation with Triton-x (TX) and block with Bovine serum albumin (BSA) 
solutions, then transpirize in Glycerol solution overnight.   
More specifically, the spheroids after the LIVE/DEAD assay were washed with PBS three 
times 5 minutes each, immobilized into an agarose pad and fixed with Paraformaldehyde 
3.7% for 40 minutes and then washed again as above. At this point the spheroids immobilized 
into the agarose pad were gradually permeabilized: 20 minutes with PBS + 0.5% Triton-x 
(TX), 3 times with PBS + 0.1% TX 10 minutes and PBS + 2% BSA (bovine serum albumin) 
+ 0.1% TX 40 minutes and then washed as above. Finally the PBS was replaced with glycerol 






3.4. Results  
 
3.4.1. The growth rate of multicellular spheroid embedded in agarose gel 
The multicellular spheroids were embedded in agarose gel in order to develop a progressive 
controlled growth-induced compressive stress. The spheroids size evolution was followed 
over several days.  
In a first attempt to obtain spheroids embedded in an agarose matrix, we directly mixed the 
cell suspension with the unpolymerized low-melt agarose matrix as suggested in the protocol 
of Helmlinger and colleagues (110). When the agarose polymerized, the cells remained 
trapped into the matrix and from each single cells or small cell aggregates a spheroid was 
formed. In this way, however, given the quantity of spheroids that formed in each well, it was 
impossible to follow the evolution of the same spheroid, so we calculated at every time point 
an average size from all the visible spheroids. With this method we obtained spheroids of too 
variable dimensions coming from aggregates with different cells number. It is obvious to 
understand that to evaluate a phenomenon at best you must have as few variables as possible, 
so we looked for a strategy to have MCSc with comparable size and to track them over time. 
For this reason, rather than embedding single cells as it was previously performed, a new 
protocol to trap the whole spheroid was developed and to track it more easily in time. The 
new embedding method proposed in this study is reported in the fig. 19a-b.  It essentially 
consists in mixing a 2/3 days-old spheroid with a low melt agarose matrix at 37°C and then to 
induce a fast polymerization of the agarose on ice. After that the spheroid is allowed to grow 
under confinement for 2 more days and is then treated with the drug.  
Before this protocol, we tried different strategies to embed the spheroid: at the beginning we 
simply covered the spheroid with low melt agarose, but that embedding was not optimal. We 
noticed that in most cases, the spheroid in the liquid polymeric matrix tended to sediment at 
the bottom of the well in less than one minute. Considering that at room temperature the 
agarose needs about ten minutes to polymerize, the spheroid would eventually be at the 
bottom when the agarose is solid. Such embedding is not fully 3D: spheroids would not to 
feel the same compressive stress on its entire surface. For instance, some cells escape the 
spheroids and start to grow in 2D on the bottom of the contacting well.  In fact, the key step of 
this is the rapid ice polymerization necessary to trap the spheroid into the polymer matrix 
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before it sediments by gravity. Polymerization on ice did not 
affect the spheroid. The control was subjected to similar ice conditions and grew well.  
Moreover, the agarose hydrogel remains a poorly characterized material, and that one has to 
be careful with the mechanical stress calculation when performing such experiments. Our 
colleagues in Lyon perform rheological measurements on the agarose hydrogel and using this 
calibration, we were able to extract growth-induced pressure curves for embedded spheroids. 
In particular they found a rough linear increase of normal stress applied onto the spheroid 
during growth as shows the figure 20. 
 
Figure 20. Growth-induced pressure as a function of time extracted through the growth of spheroids in 1% low-melt 
agarose. Mean values are plotted, shading corresponding to ±SD over N ≥10 spheroids. 
The figure 21a shows the growth trend in 8 days of spheroids growing in 0.5% (red line) and 
in 1% (blue line) of agarose versus their correspondent control spheroids (black line). We 
report in this graph the spheroid’s mean radius normalized to initial radius as a function of 
time in days. The increase of agarose matrix concentration progressively reduces spheroid 
growth. A representative picture of an agarose 1% compressed spheroid and its size is 
reported in the figure 21b (right): it can be seen how the size of the spheroid is smaller than its 
control (20b – left). In particular compared to the control, a spheroid under 7 days of 1% 
agarose compressive stress grows about 40% less. The results are consistent: the errorbar is 




Figure 21. Compressive agarose embedding stress decrease spheroids growth. (a) agarose 1% (red) and 0.5% (blue)  
embedded spheroids growth curves versus their control (black) – x axis : time (days) ;  y axis : unit normalized mean radius - 
Mean values are plotted, shading corresponding to ± SD over N ≥10 spheroids. b) Representative size of  control and 
agarose embedded stressed spheroids after 7 days under compression. 
 
3.4.2.  Dextran osmotic effect on multicellular spheroid growth rate.   
In order to exert a mechanical stress, a biocompatible polymer, Dextran (MW = 100 kDa) was 
added to the culture medium after the formation of the spheroids. Unlike more physiological 
osmolytes, such as glucose or ions (Na+, Mg2+, etc), dextran macromolecules are not 
internalized by cells, and do not infiltrate the intercellular space of spheroids if large enough 
(several tens of kDa) (107). It has been demonstrated in a previous paper that dextran does not 
penetrate the spheroid. Accordingly, the same osmotic effect on the spheroid growth is shown 
with a dialysis membrane interposed between the spheroid and the dextran molecules (169). 
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The effect we observe is not a direct osmotic effect on single cells, as is often described in the 
literature for high osmolarity shocks. The compressive stress can be seen as a network stress 
that tends to reduce the volume occupied by the MCS (106). In this regime, dextran is not 
affecting component concentration of single cell but rather of spheroid. Thus, they exert a 
constant osmotic stress onto the whole spheroid and induce an efflux of water from the 
spheroid, probably from the matrix components (107) (171). The stresses used are 0.5 kPa, 
1kPa and 2kPa and it is worth noting that these are small stresses even 5 kPa is a rather small 
stress and it correspond to the osmotic pressure exerted by 1 mM NaCl. 
Interestingly, for a stress of 5kPa, the spheroids decrease their volume: some cells probably 
die because of the high dextran concentration. 
In the figure 22a we show the evolution of spheroids size under compressive osmotic stress of 
1kPa (red line) and 2kPa (blue) in comparison with their control (black line). The results are 
comparable to those in agarose:  in both cases, an increase of compressive stress reduces 
proportionally the growth rate of multicellular spheroids. A representative picture of a 1kPa 
osmotically-compressed spheroid and its size is reported in the figure 22 b (right): it can be 
seen how the size of the spheroid is smaller than its control (22 b – left). In particular 
compared to the control, a spheroid under 7 days of 1 kPa dextran compressive stress grows 
about 33% less. 
It is important to underline that, although in this case we have obtained an inhibition of the 
growth of the spheroid under stress, we are dealing with a different stress than the one 
agarose-induced. In particular, both of these are compressive stresses, but the one mediated by 
agarose is growth-induced, while the dextran is osmotic and constant. We observed that 
osmotically compressed spheroids restricted cell proliferation to the outermost layers. The 







Figure 22. Osmotic dextran stress decrease spheroids growth. (a) osmotic dextran 1kPa (red) 2kPa(blue)  stressed 
spheroids growth curves versus their control (black) -  x axis : time (days) ;  y axis : unit normalized mean radius - Mean 
values are plotted, shading corresponding to ± SD over N ≥10 spheroids. b) Representative size of control and osmotic 
stressed spheroids 1kPa after 7 days under compression. 
 
 
3.4.3. Cryosection and immunofluorescence biological characterization 
In addition we performed immunostaning of paraffin-embedded spheroids section to evaluate 
the compressive stress effect on the proliferation and cells death (figure 23). We analyzed the 
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spheroid grown under 1% agarose and 1kPa dextran compressive stresses for 4 days and their 
corresponding control. To label cell division we used the antibody against Ki67 and to label 
apoptosis the antibody against cleaved-caspase-3. As can be seen in the figure 23, into the 
spheroid there is a gradient of cell proliferation from the inside out but this gradient is reduced 
under compressive stress. Compressive stress reducing cell proliferation and subsequently S-
phase entry.  Moreover, we do not observe any significant apoptosis at the surface or in the 
inner layer of the spheroid where the compressive stresses are exerted. 
 
Figure 23. Effect of stress on the distribution of proliferation and apoptosis. Cryosections and immunofluorescence of the 
spheroids are used to label the cell divisions [antibody against Ki-67 purple- first line] and apoptosis [antibody against 
cleaved Caspase-3 in dark red – second line)]. (Left)  Spheroid grown in a normal medium for 4 days. (Middle)  Spheroid 
grown with a stress of1% of agarose (right)and 1 kPa dextran for 4 days. 
 
3.4.4. A compressive stress reduces proliferation of pancreatic cancer multicellular 
spheroids: capillary Western blot results. 
We investigated whether the reduced growth rate due compressive stress affected 
proliferation. Since the sensitivity of a traditional western blot requires a “considerable” 
amount of proteins (typically corresponding to about 20 spheroids), we decided to perform a 
capillary Western blot analysis, for which the protein quantity of about five spheroids is 
sufficient. This is certainly a huge gain of time; practically in the time of a single experiment 
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we could get 3 independent replicates. The capillary Western blots were performed on 
spheroids compressed by Dextran. Capillary western blotting is a new automatic protein 
separation and immunodetection based on the application of the Protein Simple capillary 
immunoassay (Wes) method, a gel- and blot-free. Wes requires less sample, antibody and 
time to run than conventional western blot assay. The machine Automated Western Blot from 
Protein Simple Company (Wes) and its corresponding preparation kits were used for a high 
performing capillary Western blot.  In Wes, proteins are size separated in capillaries, where 
they are incubated with primary and (HRP-conjugated) secondary antibodies and finally with 
Luminol/peroxidase. The produced chemoluminescence is detected at multiple exposure times 
and automatically quantified by the Compass software. The chemoluminescent signal can be 
displayed as an electropherogram or as a virtual blot-like image. The electropherogram shows 
the intensity (per second) detected along the length of the capillaries, and shows automatically 
detected peaks, that can be quantified by calculation of the area under the curve (AUC). 
ERK was used as proliferation marker. ERK is a mitogen protein kinase involved in many 
cellular programs, such as cell proliferation (185). The ratio phospho-ERK to total ERK is a 
marker of cell survival and proliferation. The cyclin dependent kinase inhibitor 1B (p27) was 
used to identify proliferation inhibition which controls the cell cycle and progression in G1 
(106) and the cleaved-caspase 3 was used as an apoptosis marker (185). Generally in the 
western blots proteins such as actin, tubulin or histone H3, etc. are used as loading control, 
but in our case they could all change under pressure. So we tried to get around the problem 
loading a similar total volume of cells assuming cell density was roughly constant. For 
instance, we loaded 5 spheroids of the control of volume V0, and 10 spheroids of dextran 
condition of volume V0/2.  
We report in figure 24a the assay plate and manufacturer's loading protocol. In the first line 
the samples are loaded, and the same sample is repeated every time it has to be analyzed with 
a new antibody, the sample will then be found in the column corresponding to the antibody 
with which it must be checked. The primary antibodies are loaded in the C row, the secondary 
ones in the D row and the luminol-peroxide in the E line. 
It is essential to calibrate well the sample dilutions to remain within the instrument's range of 
detectability. Often the same sample dilution cannot be used with different antibodies because 
the protein expression is different: for example, in comparison to p27, for the same sample, 
pERK and ERK have to be diluted 3 times. 
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Figure 24b shows the pERK/ERK and p27 protein expression in the osmotic compressed 
spheroids compared with their control (dashed line). 
 
Figure 24. Capillary Western blot analysis (Wes) : (a) assay plate and manufacturer's loading protocol ; (b) p-ERK/ERK 
and p27 expression into dextran osmotic compressed spheroids. 
 
A decrease of pERK/ERK and an increase of p27 expression in osmotically stressed spheroids 
suggests that the reduction in growth rate of compressed pancreatic cancer spheroids is 
accompanied with/is the consequence of a decrease in single cell proliferation within the 
spheroid, consistent with the immunostaining.  
3.4.5. What happens to the efficacy of a proliferation targeting drug when the 




We treated freely growing multicellular spheroids with gemcitabine to investigate the nominal 
effect of this chemotherapeutic. Perhaps not surprisingly, we found that spheroids subjected to 
10µM gemcitabine decreased in size (Fig. 25 a). The decrease was apparent after an average 
of 1 day post drug addition, consistent with the fact that only S-phase cells are sensitive to the 
drug.  
 
Figure 25. Effect of gemcitabine on the free growth of spheroids. a.  Representative pictures of freely growing pancreatic 
spheroids and exposed to gemcitabine (left). Drug was added after two days of growth. Growth quantification over time. 
Mean values are plotted, shading corresponding to ± SD over N ≥ 10 spheroids (right). b. capillary Western blot analysis of 
spheroids. Phosphorylated form of ERK (pERK) normalized to total ERK is used as a proxy for the amount of cell 
proliferation, and cleaved-caspase 3 as a proxy for the amount of dying cells. The data under gemcitabine treatment are 
normalized to the control.  
We performed capillary western blots to investigate the changes in proliferating and dying 
cells under gemcitabine treatment. We measured the ratio between a phosphorylated form of 
ERK (pERK) over total ERK as a proxy for cell proliferation and the amount of cleaved-
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caspase 3 as a proxy for cells undergoing programmed cell death (Fig. 25 b). A considerable 
increase in the cleaved-caspase 3 expression in Gemcitabine treated spheroids tells us that the 
drug is working with its maximum efficacy increasing cellular apoptosis. We observed that, as 
the amount of proliferating cells decrease under drug treatment, the amount of dying cells 
increased by roughly, in agreement with gemcitabine preferentially killing proliferating cells.. 
We next sought to investigate the impact of compressive stress pressure on the efficacy of 
Gemcitabine. After compressing the cells for 2 days, either mechanically with agarose or 
osmotically with Dextran, we treated the spheroids with 10µM Gemcitabine, and measured 
the evolution of the spheroids’ size over time (figures 26a and 26b). We compared the results 
with the correspondent controls: free spheroid and free spheroid + Gemcitabine. 
 
Figure 26. (a) Compressive agarose embedding stress decrease spheroids growth and the chemioterapic drug efficacy. 
agarose 1% (red) and 0.5% (blue)  embedded spheroids growth curves versus their control (black) ; Gemcitabine (Gem) 10 
µM efficacy into agarose 1% (red) , 0.5% (blue)  embedded and control spheroids (black) – complexive chart on the left – x 
axis : time (days) ;  y axis : unit normalized mean radius. (b) Osmotic dextran stress decrease spheroids growth and the 
chemioterapic drug efficacy. Osmotic dextran 1kPa stressed spheroids growth curves (red) versus their control (blue); 
Gemcitabine 10 µM efficacy into dextran 1 kPa (osmotic stressed (violet) and control (yellow) spheroids–– x axis: time 
(days); y axis: unit normalized mean radius. 
We found that the drug was less efficient under compressive stress: compressed spheroids are 
less sensitive to the drug than unconfined/uncompressed ones, their size reducing much 
slower as compression increased. 
Figure 27a shows the agarose-embedded spheroids evolution at 6 time points: Time 0 (the day 
when the agarose mechanical stress is applied), 1 day, 4 days, 7 days, 8 days, 12 days. There 
are 4 conditions: control, control + Gemcitabine, 1% agarose embedding and 1% agarose 
embedding + Gemcitabine. Two cases are shown for the 1% agarose embedding + 
Gemcitabine: the case where the spheroid is still fully embedded in the agarose and the case 
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where the spheroid’s size decreased below the initial size at embedding and is not confined 
anymore.  
 
Figure 27. Agarose embedded spheroids + Gemcitabine evolution. (a) microscope pictures of controlled, controlled + 
Gemcitabine, 1% agarose and 1% agarose + Gemcitabine spheroids growth without agarose relaxation (fourth row) and 
with agarose relaxation (fifth row) ; (b) size evelotion of controlled + Gemcitabine spheroids 6 days shifted (black), 1% 
agarose + Gemcitabine spheroids  without agarose relaxation (blue) and 1% agarose + Gemcitabine spheroids  with 
agarose relaxation (pink). Beyond the dashed line the spheroids are not confined by agarose. 
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So, in the first case the agarose exerts on the spheroid a growth induced compressive stress as 
explained above but, in the second case, at some point, such stress disappears. After 
relaxation, it seems that the spheroid resumes its normal proliferative capacity and when this 
happens Gemcitabine regains its nominal efficacy. We consider as nominal the efficacy that 
Gemcitabine has with a spheroid not subject to any compressive stress (control + Gemcitabine 
condition). In the figure 27b we compared with the respective control shifted for 6 days (black 
line) the two conditions with (pink line) and without (blue line) agarose relaxation. The 
dashed line indicates the time point at which the confinement relaxes on average. After 5-6 
days of drug treatment under confinement of spheroids which did not grow much initially, the 
reduction of the radius was such that the spheroids were not confined anymore and as such 
did not experience any compressive stress. The behavior with Gemcitabine of the embedded 
spheroid in the case of agarose relaxation is totally comparable with the free spheroid and in 
agreement with our hypothesis. Quiescent cells would re-enter the cell cycle, proliferate 
faster, and consequently die faster. This is what we found experimentally: a slow initial death 
rate during compression, followed by a faster one in the unconfined phase. Moreover, it is 
interesting to note that this experiment suggests that the proliferative capacity of the spheroid, 
reduced by compression, is perfectly reversible. This mechanism makes two hypothesis: If the 
efficacy of a proliferation-based chemotherapeutic is decreased because of a mechanical 
modulation of cell proliferation, then the observed modulation of efficacy (i) should not 
depend on the type of mechanical stress applied, but rather on the fact that mechanical stress 
could decrease cell proliferation (as we demonstrated with Dextran) and similarly, (ii) should 
not depend on the type of drug used, but rather on the fact that the chemotherapeutic drug 
targets proliferating cells. 
 
3.4.6. Agarose embedding spheroid growth with Docetaxel 
 
Our results suggest that the mechanical stress decreases the efficacy of the drug by acting on 
specific signaling pathways linked with cell proliferation.  Then, probably the effect that we 
see is not Gemcitabine-dependent, but another drug acting on proliferation, as Gemcitabine,  
could also see its efficacy decrease as a function of mechanical stress. We tested this 
prediction with docetaxel, acting during mitosis by stabilizing mitotic spindle. 
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First, we made a comparison of the efficacy of Gemcitabine, Docetaxel and the specialized 
nanocarrier SPNs carrying Docetaxel (fig. 28). In this scenario we decided to test the SPNs, 
because, as we mention above, is well-known their potential to target solid tumors (182).  
 
Figure 28. Gemcitabine vs Docetaxel vs Docetaxel-SPNs. Control spheroids (blue line), Gemcitabine treated spheroids (red 
line), docetaxel treated spheroids (green line) and SPNs-Docetaxel treated spheroids (yellow line). 
In the treatment of pancreatic cancer, Gemcitabine certainly appears to be more effective, 
although Docetaxel is well known as second-line chemotherapy on PDAC cells (180). The 
nanoconstructs are spherical in shape with a characteristic diameter of about 100 nm, which is 
ideal for targeting solid tumors via the enhanced permeability and retention (EPR) effect. 
However, from the analysis of the spheroid diameter, the particles would seem to be the least 
effective, but given their adhesive capacity, they tend to release big quantity of the drug in the 
innermost part of the spheroid destroying not only superficial cells but also internal cells. This 
implies that a quantification of the evolution of the spheroid radius is not sufficient to quantify 
the real effect of these nanoconstructs. These are only preliminary results that should be 
further explored.  
Finally, we sought to investigate on our second hypothesis, explained above, i.e. the effect of 
mechanical on the drug efficacy should not depend on the type of drug used, but rather on the 





Figure 29. Experimental consistency demostration of the agarose embedding experiment with Docetaxel. 
 
We confined spheroids in 1% agarose gel similarly to what we previously described, and 
treated the compressed spheroid after 2 days under mechanical compression with 10 µM 
docetaxel. Preliminary data suggest that indeed mechanical compressive stress of agarose 
reduces the efficacy of this other chemotherapeutic drug, docetaxel, consistent with our 
prediction (fig 29).  
 
3.4.7. Biological Characterization:  Clearing of spheroids by transparization and live-
dead assay  
 
We developed an imaging strategy to compare the effect of Gemcitabine and docetaxel, and to 
localize SPNs: the transparization assay. Along with this, we used a LIVE/DEAD assay to 
estimate the cell viability into the spheroids. In particular we applied first the live/dead assay 
because the transparisation test involve cell fixation and therefore cell death. 
The LIVE/DEAD assay provides a two-color fluorescence cell viability assay that is based on 
the simultaneous determination of live and dead cells with two probes that measure 
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recognized parameters of cell viability intracellular esterase activity and plasma membrane 
integrity.  The molecular probes are calcein AM and ethidium homodimer (EthD-1).  The 
calcein is well retained within live cells, producing a green fluorescence, while EthD-1 enters 
cells with damaged membranes and undergoes an enhancement of fluorescence upon binding 
to nucleic acids, thereby producing a bright red fluorescence in dead cells. 
The imaging of 3D cell cultures is highly challenging due to high thickness, which results in a 
light-scattering phenomenon that limits imaging. Unfortunately, light scattering prevents 
confocal imaging beyond a typical depth 50 µm in tissues (186).  The ability to resolve and 
segment individual cell nuclei in 3D culture models is a necessary prerequisite for performing 
high spatial resolution measurements and quantitation of microenvironment effects: in other 
hands should be possible to distinguish different cell subpopulations into the spheroids. 
Herein we present a protocol for cell clearing / transparization in spheroid models (full 
explanation in the session Transparization protocol of the Methodologies).  
The figure 30 shows the resulting confocal pictures from a control, a Docetaxel treated and a 
Docetaxel – SPNs (DTXL-SPNs) treated spheroid (fig. 30a).  
We are perfectly able to recognize live cells from dead cells within the spheroid but it is not 
possible to make a real quantification of the dead cells: dead cells would hardly stay confined 
in the spheroid. Anyway, live/dead assay suggests that cell death is located at the inner area 
for the control, at the periphery for the Docetaxel treated and in both areas for the DTXL-
SPNs treated spheroid. This is consistent with the fact that spheroids are stratified with an 
outer rim of proliferating cells that is the chemotherapeutic target. Moreover, the particles, as 
it explained above, given their adhesive capacity, tend to release big quantity of the drug in 
the innermost part of the spheroid destroying not only superficial cells but also internal cells. 
The figure 30b is a confocal bright-field picture from a cleared spheroid: it is possible to 
distinguish the nuclei from both inner and peripheral spheroid areas, and the genetic material 
can even be seen inside (small white dots). This means that method has been successful: cell 






Figure 30. Confocal pictures of cleared spheroids by transparization and live dead assay. (a) live-dead / transparization 
assay result from control, Docetaxel treated and Docetaxel – SPNs (DTXL-SPNs) treated spheroids. In green living cells, in 
red dead cells, in blue cells nuclei and in Magenta DTXL-SPNs. (b) bright-field picture of cleared spheroid by 
transparization assay protocol.  
  
Quantitation of microenvironment effects in 3D cultures is essential, as cells within tissues 
may have different drug responses. Herein we present a protocol for high-throughput nuclear 
segmentation in spheroid models. This is an integrated tool to distinguish and quantify the 
different spheroid cellular subpopulations. 
3.4.8. Effect of Substrate Stiffness/Rigidity on cells drug sensitivity. 
Cells reside in various matrix stiffnesses throughout the body. Tissue culture plastic wares 
have an elastic modulus of 1 X 107 kPa whereas tissues/organs have much lower values 
ranging from 0.1 to 100 kPa (187) (188) (189) (190) (191) (192) (193) (194) (195) (bones 
excepted). Cells in the body interact with their local 3D microenvironments, which can vary 
based on tissue location and disease states. The CytoSoft® Elastic Modulus Plates were used 
to tested the Gemcitabine efficacy in more relevant in vitro cell models: these substrates more 
closely represent native tissue rigidities (0.2 – 64 kPa). We investigated the role of substrate 
stiffness as an additional source of mechanical stress that can modulate cell proliferation. 
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The plates must be coated with an extracellular matrix protein prior to cell addition. For this 
reason we tested the cell adhesion proteins poly-L-lysine, gelatin, collagen and fibronectin 
(fig. 31a). Cells growing on all substrata but fibronectin seem to create aggregates, which then 
limit the 2D assay we wish to investigate; for this reason, we choose to use fibronectin as a 
coating of the plates. 
 
Figure 31. Effect of Substrate Stiffness/Rigidity on cells drug sensitivity. (a) Rigidity plate coating test with Polylysine, 
Gelatine, Collagen and Fibronecti ; (b) Cytonote time lapse analysis of the Gemcitabine efficacy at 0.5 kPa and 64 kPa of 
rigidity. 
 
We analyzed the growth of cells with two different stiffnesses (64kPa and 0.5 kPa) and 
evaluated the efficacy of Gemcitabine 10µM (fig 31 b). At 0.5 kPa the cells seem to grow 
more slowly than at 64 kPa. This is accompanied with a decrease in the efficacy of drug. This 
set of data is consistent with the fact that mechanical stress can affect the efficacy of a 
proliferation-based chemotherapeutics by modulating the very cell proliferation index. 
Using the substrate stiffness/rigidity stress we have confirmed once again the previous result: 





3.4.9. A mathematical model perfectly predicts the effect of compressive stress on drug 
efficacy. 
Pietro Mascheroni, a theorist collaborator, developed a mathematical framework to model the 
chemotherapeutic efficacy under dextran and agarose compressive stresses (see insert for 
detailed calculation). In brief, we consider a spheroid as a stratified three-dimensional 
structure, with cells proliferating in the outer rim, and quiescent in the center. 
We assume that the total number of cells in the spheroid varies according to cell proliferation, 
drug-induced death and apoptosis. In particular, cell proliferation is exponentially distributed 
over the spheroid radius, with a characteristic length L. Cell death induced by the drug acts on 
proliferative cells, whereas apoptosis takes place over the entire spheroid radius. We observed 
that cell death induced by the drug is not instantaneous. Indeed, in order for the drug to be 
effective the cells must be in the proliferative state. The waiting time for the cell to enter the 
proliferative phase can be assumed to be exponentially distributed, giving a delay for the drug 
to be effective of about 24 hours. Assuming (i) that the characteristic proliferation length L is 
smaller than the spheroid radius and (ii) that the experiments are performed over a timescale 
in which apoptotic death is not fully developed, we can write the temporal variation of the 
spheroid radius R as 




where g is an effective growth rate (including the early effects of cell apoptosis) and d is the 
death rate induced by the drug, including the time delay (for more details, the reader is 
referred to the insert). In writing this equation we assumed that d is independent of the 
external pressure applied to the spheroid. The dependence on pressure is only considered for 
the growth rate g which takes the value g0 in control conditions (i.e. no compression and no 
drug). 
We use the experimental data to fit the various parameters of the model: g=g0 is fitted through 
the control experiment, g=gc is obtained from the spheroid growing under compression, and 
the drug induced death rate d=d0 is calibrated when the drug is administered to the spheroid in 
the absence of pressure. Using the fitted parameters, we use the model to predict the 
combined effect of compression and drug action, and find a good agreement with the 




Figure 32. Model results for the growth of spheroids under different external conditions. Model calibration is represented 
by solid lines, whereas the dashed line represents model prediction. (a) Agarose embedding stress; (b) Spheroids exposed to 
gemcitabine can eventually be smaller that the initial inclusion size, and are subsequently unconfined (pictures in inset). The 
model is able to capture the effect of gemcitabine in this case, switching from efficacy of confined cells before 6 days, to 
efficacy of unconfined cells after 6 days. (c) dextran compressive constant stress.(d) agarose confined spheroid growth 
with docetaxel In all cases, mean values are plotted, shading corresponding to ± SD over N ≥ 10 spheroids. 
 
This model was able to predict the effect of compressive stress on Gemcitabine drug efficacy 
into mechanical agarose compression (32a), also in the case of agarose relaxation (32b). 
Moreover it predicted the spheroids growth under osmotic Dextran compression (32c) and 
confirmed the effect of the other chemotherapy that we tested, such as docetaxel (figure 32d). 
The excellent prediction of the model with the experimental data is consistent with a 
mechanism where mechanics would decrease chemotherapeutic efficacy through a 
modulation of cell proliferation independent of stress and the drug used (in the model we 
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assume that effect of the drug effect and the mechanical stress are not coupled). The 
rigidity/substrate effect experiments cannot be fitted with this model but in any case seem to 
be consistent and confirm what we reported with the other stresses. 
 
3.5. Conclusions and perspectives 
3.5.1. Conclusions  
 
In this work we investigated the impact of mechanical stress in the efficacy of drug treatment 
and we arrived at three main conclusions. 
1. Reduction in growth rate of compressed pancreatic cancer spheroids. 
We performed a new strategy to embed whole PDAC spheroid in an agarose matrix.  
The agarose represents a good candidate to mimic the elastic stroma behavior during 
the tumor progression, because such as the stroma, accumulates an elastic stress 
during tumor progression and, in function of it, elastically reacts.    
In this work, a strong reduction of PDAC spheroid growth in the presence of stress 
was reported and we demonstrated that spheroids growth decreases with increase 
stress.  
We decided to give a greater value to these results by testing another mechanical 
compressive stress: osmotic stress mediated by a high molecular weight Dextran. It is 
known that the Dextran is non-toxic with mammalian cells and, given its size, is not 
able to penetrate either the cell or the spheroid inducing a constant osmotic stress to 
the whole spheroid. The effect on the tumor spheroid growth, even in this case, 
resulted inhibitory but it must be pointed out, that the dextran stress is constant and 
agarose is a progressive compressive mechanical stress. For further demonstration of 
these results we tested the rule of mechanical tensile stress in 2D confirming the main 
idea that mechanical effects can have strong implications in cancer progression.  
2. The lower growth rate of a spheroid is a consequence of a decrease in single cell 
proliferation. The previous observations suggest that the growth rate reduction after 
the application of the compressive stress controls the proliferation of the MCS. 
With the use of the high-performance mini-Western blot technique we analyzed the 
protein expression of spheroids under stress. In particular, the expression of pERK and 
p27 were evaluated.  It was evident from the massive increase in the expression of p27 
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in compressed spheroids that compressive stress inhibits the proliferation of individual 
cells in the spheroid. Therefore we can conclude that our results show that direct 
mechanical effects can have strong implications in cancer proliferation. 
3. Evidence that the mechanical stress affect the efficacy of a proliferation-based 
chemotherapeutics. 
Once we understood that the reduction of growth rate indicated even a reduced 
proliferative index we investigated what was the efficacy of a proliferation-based 
chemotherapy. We found a Gemcitabine efficacy decrement when spheroids 
proliferate less because of agarose compression. Then, we confirmed the agarose 
result with another mechanical stress, such as the dextran osmotic stress, and the 
Gemcitabine result with another chemotherapic, such as docetaxel. 
Until now, drug-resistance have been studied from a cell-centered point of view not 
considering the surrounding environment but our results proved that stromal 
components could also participate in the mechanisms of drug resistance. In addition, 
they could explain the large fraction of drugs failing clinical trials but passing the pre-
clinic.  The mechanisms coupling drug resistance to mechanical stress could both 
inform on approaches to better delineate chemotherapeutic strategies and design new 
screening platforms. 
Therefore, although stromal subtyping is still in its infancy, it may turn out to be an 
important stratification tool for future therapies. 
To conclude this work it is still necessary to confirm the data with tensile stress and to 
investigate more on the spheroids protein expression especially on the agarose compressed 
spheroids. To analyze the spheroids embedded in agarose with the capillary Western blot 
there are some practical impediments: for instance, the spheroid has to be removed from the 
agarose matrix, which could lead biological perturbations. Therefore, in parallel we are 
looking to develop an innovative cryosection and immunostaining protocol.  
In addition, it would also be nice to check the Docetaxel delivery from the SPNs (Spherical 
polymeric Nanoconstructs) particles in this solid system that allows us to tune the mechanical 
stress on the tumor progression. The SPNs already proved in vivo the targeting of solid 
tumors. Actually we have just some preliminary results, and to this regard, the transparization 
assay has proved to be a valid analysis tool. 
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3.5.2. Discussion and future perspectives 
Compressive mechanical stress can affect any cell population that proliferates in a space-
limited environment (196). However, until now, the study of compressive mechanical stress 
has been limited owing to the experimental difficulty of imposing a controlled compressive 
stress. 
Our results suggest that increasing the concentration of agarose reversibly decreases 
pancreatic cancer spheroids volume growth. Comparison of spheroids response to 
chemotherapy under each condition showed that increasing the concentration of agarose 
decreases the spheroids growth and the single cell proliferation rate, and consequently 
decreases the chemotherapy responses. The combination of results suggests that limiting 
growth due compressive stress leads to a drug-resistant phenotype. Mechanical compression 
results in diminished drug responsiveness and spheroids in high stiffness of agarose are less 
responsive to chemotherapy. A mechanical-form of drug resistance exists: the efficacy can be 
directly altered by a mechanical-control of cell proliferation. The theoretical prediction of the 
experimental data, with the assumption that mechanical stress and pharmacological activity 
are decoupled, strongly supports this mechanism. The idea that quiescence can be a dominant 
mechanism leading to drug resistance is appreciated (197), but has never been linked to 
mechanical stress. Our data can potentially explain the reduced effect of chemotherapeutics of 
mechanically stressed cells (198) (199), although it remains to be demonstrated. 
In addition, from a pharmacological point of view, we can say that a drug dose that is 
effective in reducing tumor volume for stress-free conditions does not work as well in a 
mechanically compressed environment. As an extrapolation, the extensively used drug 
screening system needs to be revalued and redesigned. 
The tumor stroma, including its diverse cellular and non-cellular components, affects cancer 
progression and tumor response to therapy in multiple ways. Classical therapies of cancer 
focused on the transformed clonally expanded cell as the primary target for tumor detection 
and targeted intervention. Over the last years it became clear that the tumor microenvironment 
offers additional targets for detection and therapy. Tailoring such treatment to the patient 
requires effective means for analysis of such targets and for detection of the efficacy of 
intervention. An in vitro system like ours could fill this gap. However, it is clear that we have 
just begun to reveal the rich and rapidly changing landscape of the tumor stroma, and thus 
many challenges remain.  
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More work has to be done on the solid mechanics of cancer, opening new avenues for future 
basic or translational research. As regards basic research, a more detailed mechanical 
characterization of the surrounding solid tumors and host tissues is necessary. As regards the 
areas of translational research, first priority should be given to the definition of specific rules 
for stress reduction strategies. This involves the re-use of clinically approved drugs or the 
development of new drugs that can be used as stress alleviating agents. This should lead to the 
derivation of specific dose protocols, which, given the highly heterogeneous and dynamic 
nature of cancer, should be different among tumors and give rise to patient-specific protocols. 
For instance, an enzyme is currently under clinical trial, such as the hyaluronidase in its 
pegylated-form, that digests hyaluronic acid reducing matrix swelling and, in combination 
with gemcitabine, increases chemotherapeutic efficacy (200). As we have seen, one of the key 
characteristics of PDAC progression is overproduction of hyaluronic acid and this solution 
has shown good potential. It is thought that the promising results are due to a reduction in 
solid stress that restores the tumor perfusion or part of it. However, it remains unclear how the 
hyaluronidase and Gemcitabine really work.  Based on our results, for example, we could 
think that hyaluronidase, in addition to improving tumor perfusion, could mechanically 
modulate cell proliferation.  
Collectively, in the antitumor battle, another goal to look for could be enforcing the tumor 











4. Global Conclusions and prospective  
 
In the first part of this study, the methods to develop more effective nanomedicines within the 
tumor system were evaluated. We have seen how the physical characteristics of the particles, 
such as shape, size, polymeric composition, loading and release capacities, could influence 
their success. Specifically, we focused our attention on some specific general features of the 
tumor, such as EPR effect, reduced blood flow in tumor vessels, red blood cell behavior and 
immune response But, the tumor system is highly heterogeneous and the tumor 
microenvironment is constantly evolving, then the optimal design of nanoparticles should 
likely be disease specific or tumor stage specific. In fact, in the second part of this work we 
discovered the importance of mechanical stress in compressed pancreatic tumor. It was seen 
that compressive mechanical stress reduced the proliferation of individual cells of a tumor 
spheroid and that this led to a reduced action of a proliferation-based drug. 
The phenomena listed above are fundamental for the development of nanovectors, but if the 
cells in the tumor site were not reactive to chemotherapeutic drugs, what use would the efforts 
to develop nanovectors so efficient in reaching the target site and release the drug? That is, if 
the problem was not the efficiency of the nanovectors but the cell reactivity? 
Specifically, in solid tumors, which represent 90% of human tumors including carcinomas 
and sarcomas, cell proliferation is followed by a progressive stiffening of the tissue, 
eventually becoming stiffer than healthy tissue. This phenomenon explains why tumors are 
frequently detected through physical palpation as they appear as a rigid mass residing in 
healthy tissues. For instance, pancreatic cancer at some point develops a stress that may 
inhibit proliferation, and consequently, make tumor cells inactive towards chemotherapy in 
general. So, the nanomedicine and chemotherapy in general, in order to achieve better results, 
should act with a broader view of the phenomena that occur during malignant development, 
and incorporate the “physics of cancer”.  
We saw in the literature how the mechanical phenomena, minimally explored up to now, are 
demonstrating an important role in the tumorigenesis and consequently in the anti-cancer 
therapy, to the point of developing a new science: physical oncology. All these physical 
hallmarks of cancer, although not fully understood, are inspiring new anticancer strategies 




In particular, an original paradigm shift as future aim of this work could be the design of 
nanomedicines that, based on the tumor microenvironment, bring agents that reduce the tumor 
pressure and rigidity. They should be activated on demand to achieve a tailored spatio-
temporal modulation of the tumor microenviroment and alleviate the resistance to current 
treatments, if necessary (201). Having the physical cues of cancer in mind, it can be important 
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During my PhD, we explored two complementary axes of research:  
1/ Can we improve the design of blood – cells inspired Nanoconstructs in terms of drug-
loading efficiency, phagocytic cells sequestration, and tumor accumulation?  
 
Publications 
“Deformable Discoidal Polymeric Nanoconstructs for the precise delivery of therapeutic and 
imaging agents”, Palange A, Palomba R, Rizzuti I F, Ferreira M, Decuzzi P *, Molecular 
Therapy- 2017. 
“Modulating phagocytic cell sequestration by tailoring nanoconstruct softness”, R Palomba, 
AL Palange, IF Rizzuti, M Ferreira, A Cervadoro, MG Barbato, Claudio Canale, Paolo 
Decuzzi. ACS nano – 2018. 
“A tissue chamber chip for assessing nanoparticle mobility in the extravascular space”, 
Valeria Lusi, Thomas L Moore, Federica Laurino, Alessandro Coclite, Rui Perreira, Miguel 
Ferreira, Ilaria Rizzuti, Roberto Palomba, Paolo Zunino, Marti Duocastella, Shoshy Mizrahy, 
Dan Peer, Paolo Decuzzi – 2019. 
“OPTIMIZING THE PHARMACOLOGICAL PROPERTIES OF DISCOIDAL 
POLYMERIC NANOCONSTRUCTS AGAINST TRIPLE NEGATIVE BREAST 
CANCER” Ilaria Francesca Rizzuti,  Miguel Ferreira, Anna Lisa Palange, Maria Grazia 
Barbato, Valentina Di Francesco, Martina Di Francesco, and Paolo Decuzzi. (Article in 
revision) 
Other activities 
Participation and Poster sessions at European Foundation for Clinical Nano-medicine, 
https://www.clinam.org,  Basel Switzerland 7-10 May: Discoidal Polymeric Nanoconstructs: 
Tuning Size, Shape, Surface properties and mechanical Stiffnes; Rizzuti IF, Palange AL, 
Ferreira M, Palomba R, Decuzzi P. 
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Participation and Poster session at CRS Annual Meeting & Exposition July 16–19 Boston, 
Massachusetts, U.S.A 
https://www.controlledreleasesociety.org/meetings/annual/program/Pages/default.aspx: 
TUMOR-ON-A-CHIP: SELECTING NANOMEDICINES FOR VASCULAR TRANSPORT 
EFFICIENCY AND ANTI-CANCER POTENCY, Ilaria F. Rizzuti, Rui C. Pereira, Chiara 
Manneschi, Annalisa Palange, Paolo Decuzzi. 
 
2/ Once the drug is locally present in the tumor, what would be the impact of mechanical 
stress on its efficacy?  
 
Publications 
“Mechanical-control of chemotherapeutic efficacy through modulation of cell proliferation.” 
Ilaria Francesca Rizzuti, Pietro Mascheroni, Silvia Arcucci, Audrey Prunet, Catherine 
Barentin, Charlotte Riviere, Helene Delanoe-Ayari, Haralampoulos Hatzirikou, Julie 
Guillermet-Guibert, and Morgan Delarue (currently in submission). 
Other activities 











a. Nanotechnology tools 
There are two types of approaches to the creation of artificial nanostructures. The TOP-
DOWN approach starts with macroscopic materials while the BOTTON-UP approach starts 
with atoms and molecules. Lithography is a TOP-DOWN technique. The objective of 
lithography is to define micro or nanometric three-dimensional structures of a device. The 
most common lithographic technique is optical lithography. 
 
1. Photolithography or optical lithography 
 
A conventional optical lithography system consists of:  a light source, a photomask, an optical 
system and the photoresist deposited on the wafer. Photolithography, also called UV 
lithography, is a process used in the microfabrication of three-dimensional and two-
dimensional structures inside a thin film or a substrate. It uses light to transfer a geometric 
design from a photomask to a photoresist or simply photosensitive resist, deposited on a 
substrate. Photolithography arises from the necessity to shape a film on a substrate (and 
replicate it in many copies, on many substrates). This happens through two distinct steps: 
 exposure (to UV light); 
 development, or selective removal of some parts of resist, depending on whether they 
have been exposed or not, through the covering with the mask. 
The fundamental steps of the lithographic process are: 
 substrate preparation; 
 coating [by spinner]; 
 pre-cooking [pre-bake or soft bake]; 
 alignment of the photomask; 
 exposure; 
 development; 
 annealing [post-bake or hard bake]; 
 other processes on the substrate so masked by the resist; 
 removal of the resist [stripping]; 





The resist consists of: 
 a non-photosensitive basic substance (resin, polymer) consisting of a set of monomers, 
with a very high molecular weight (100,000-200,000 atomic masses); 
 a photosensitive substance, sensitive to the wavelength used; 
 a solvent to reduce the viscosity and allow the substrate to be covered. 
The resist can be positive or negative: 
 positive is a type of resist for which the part of the resist that is exposed to the light 
becomes soluble during the development, while the unexposed portion remains 
insoluble to development (alkaline solutions); 
 negative resist, (generally less used) instead, is a type of resist in which the portion 
exposed to the light polymerizes and becomes insoluble to development. While the 
unexposed part remains soluble during the development (organic sovents). 
Advanced lithographic techniques with higher resolution, currently being studied as potential 
substitutes for conventional photolithography, include: lithography in the extreme UV (EUV), 
soft X-ray litography, Direct Laser Writing (DLW) and electron beam writing (e-beam), ionic 
ray writing focused (FIB) and probe lithography (202).  
2. Direct Laser Writer Lithography 
 
The significane of direct laser writing (DLW) lithography increased considerably during the 
last years (203) (204) (205).  Two-photon direct laser writing (DLW) is 3D printing for the 
microscopic world. This techniques has a resolution around 600-700 nm and goes beyond the 
smallest shapes and sizes that can be accomplished by garden variety 3D printing. 
The mechanism on which DLW is based is free radical polymerization. Hereby, a 
photoinitiator is excited by one or two-photon excitation (1PE and 2PE, respectively) into the 
first excited singlet state. Since typically photoinitiators are now designed to show a very high 
intersystem crossing (ISC) rate (>85%) the excited molecule will populate its triplet state 
from where it can react with environmental molecules forming radical compound that can 
start the polymerization reaction of the resin, which is mostly an acrylate. By carefully 
choosing the resin (206) and the photoinitiator, very solid structures with sub-micron sizes 
can be fabricated. The Heidelberg DWL 66fs is a high resolution pattern generator for mask 
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making and direct writing. Its capabilities and flexibility make it an ideal lithographic tool for 
research. It uses acousto-optic modulators to adjust the laser intensity, and acousto-optic 
deflectors to scan the beam. During an exposure, only the stage moves. The substrate is held 
down on the stage by vacuum and moves in the x-y plane. Its position is constantly monitored 
by an interferometer system with a resolution of 10 nm. The optical setup utilizes a diode 
laser (λ = 405 nm) as its light source. It can expose both 2D and 3D structures, e.g. gray scale 
lithography with thick photoresists. There are two write heads available: 4 mm & 20 mm. 
Both heads use an air-gauge to monitor N2 pressure change, which is then feedback to the lens 
piezo actuators for auto focus. During a scan, user patterns are divided into stripes along Y-
axis, each stripe contains 100 pixels. The stage moves along Y-axis to finish exposing one 
stripe, then steps in X-axis to start exposing the next stripe. The user patterns are then stitched 
together. In term of resolution, the 4 mm write head can achieve a minimum feature size of 
~800 nm, the 20 mm head can achieve a minimum feature size of ~4 µm. The 20 mm head 
writes about 12 times faster than the 4 mm head (207). 
3. Deep Reactive Ion Etching (RIE) 
Once the resist mask is prepared by lithography, the uncovered material is removed by a 
chemical etching (gas or plasma) - physical (sputter).  Reactive Ion Etching (RIE) is a plasma 
etching technique that uses reactive ions like F-  or Cl- (halogens) produced by ionizing gases, 
to interact with exposed surfaces of samples that results in chemical etching. The plasma is 
struck in the gas mixture and ions accelerate toward substrate and the reaction occurs on the 
surface (chemical).  The main advantage of the RIE is the anisotropic etching (unlike in wet 
etching) (208).  
4. Soft Lithography 
Soft lithography represents a non-photolithographic strategy based on a principle of self-
assembly and printing of a replica. It provides a convenient, effective and low-cost method for 
the formation and fabrication of micro- and nanostructures. In soft lithography, a 'stamp', i.e. a 
master with raised structures on the surface, obtained with lithography, models an elastomer 
generating structures whose dimensions can vary from hundreds of nanometers to hundreds of 
microns. 
The key element of soft lithography is the elastomeric material able to model itself and take 
the shape of the microstructured surface of a rigid master. The most widely used elastomeric 
material is polydimethylsiloxane (PDMS). PDMS has unique properties because it has an 
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inorganic dorsal siloxane and silicon-bound organic methyl groups. It has a very low glass 
transition temperature, and therefore it is fluid at room temperature but can easily be 
converted into a solid state. The applications of elastomeric PDMS have been extensively 
studied and are well documented in the literature. The prepolymers and the cross-linking 
catalyst are sold from different companies and in large quantities. The procedure provides the 
mixture of elastomeric pre-polymer and catalyst and then, they are deposited by casting on the 
master made by lithography. The monomers or pre-polymers with the catalyst, also called 
curing agent, polymerize even at room temperature, but often the cross-linking reaction is 
accelerated putting the mixture and its master at temperatures between 60 and 90 ° C. The 
interfacial properties of PDMS elastomer can be easily changed by pre-polymer modifications 
or by surface plasma treatment. PDMS presents problems that still have to be solved in soft 
litography, firstly, during the curing it shrinks araund 1% and, once hardened, it 
spontaneously swells on contact with non-polar organic solvents such as hexane and toluene. 
Because of its elasticity it is subject to a process of thermal expansion and this leads to a 
difficult precision and reproducibility in nanofabrication (209). 
5. Electronic microscopy 
 
Electron microscopy (EM) is a technique for obtaining high resolution images of biological 
and non-biological specimens. It is used in biomedical research to investigate the detailed 
structure of tissues, cells, organelles and macromolecular complexes. The high resolution of 
EM images results from the use of electrons (which have very short wavelengths) as the 
source of illuminating radiation. 
5.1. Scanning electron microscope (SEM) 
In the SEM technique, an electron beam strikes the sample to be observed; the beam is not 
fixed but is scanned. Numerous particles are emitted from the sample, including secondary 
electrons, which are detected and converted into electrical impulses that reconstruct the 
image. 
5.2. Transmission electron microscope (TEM) 
The TEM is analogous in many ways to the conventional (compound) light microscope.  In 
the TEM technique, the electrons that make up the beam pass completely through the sample. 
This, therefore, must have a reduced thickness, between 5 and 500 nm. The magnifying power 
is up to a million times. 
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The main difference between SEM and TEM is that SEM creates an image by detecting 
reflected or knocked-off electrons while TEM uses transmitted electrons (electrons which are 
passing through the sample) to create an image. As a result, TEM offers valuable information 
on the inner structure of the sample, such as crystal structure, morphology and stress state 
information, while SEM provides information on the sample’s surface and its composition. 
6. Atomic force Microscope (AFM) 
The AFM technique is based on the measurement of the weak forces (nano Newtons) that are 
between a thin tip and the atoms on the sample surface. The tip is positioned on a flexible 
arm, cantilever, at a distance from the surface below the nanometer, when the sample is 
translated along the xy plane below the tip, between surface and tip there are attractive or 
repulsive forces with a consequent deflection of the tip in the z direction. Surface morphology 
is reconstructed from the measurements of tip deflection.  
In the last years, Atomic Force Microscopy (AFM) has become a powerful tool not only to 
study the surface morphology but also the nanomechanics of all kind of samples. In particular, 
the AFM can be used to do Young Modulus and stiffness measurements. The AFM probe is 
used as a picoindentor: when the AFM probe touches the surface of sample it tries to 
penetrate the material , then the oppositional force of the sample is measured, this is the 
Stiffness (210).  
7. Multisizer coulter counter 
 
The machine provides size distribution in number, volume and surface area of the particles, 
with an overall sizing range of 0.4 µm to 1600 µm. Its response is unaffected by particle 
color, shape, composition or refractive index. Particles suspended in a weak electrolyte 
solution are drawn through a small aperture separating two electrodes through which an 
electric current flows. The voltage applied across the aperture creates a “sensing zone”. As 
each particle passes through the aperture (or “sensing zone”) it displaces its own volume of 
conducting liquid, momentarily increasing the impedance of the aperture. This change in 
impedance produces a tiny but proportional current flow into an amplifier that converts the 
current fluctuation into a voltage pulse large enough to measure accurately. The Coulter 
Principle states that the amplitude of this pulse is directly proportional to the volume of the 
particle that produced it. Scaling these pulse heights in volume units enables a size 
distribution to be acquired and displayed. In addition, if a metering device is used to draw a 
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known volume of the particle suspension through the aperture, a count of the number of 
pulses will yield the concentration of particles in the sample (211). 
8. Dynamic Light scattering (DLS) 
 
In DLS measurements the sample is illuminated by a laser beam, and the variations in 
intensity of the scattered light are measured as a function of time. The intensity variations 
measured by the detector are generated by the Brownian movement of the particles at the 
origin of the scattering. At the same temperature and viscosity, the "small" particles move 
rapidly - creating rapid variations in the scattering intensity - while the "large" particles move 
more slowly - creating slow intensity variations. The speed of the intensity variations is 
measured, and the particle diffusion coefficient calculated by the correlation function. Then, 
the Stokes - Einstein equation converts the diffusion coefficient into a hydrodynamic 
diameter. The measurement of the zeta potential serves to predict the dispersion stability or 
electrostatic interactions, and to measure the isoelectric point. Most particles or nanoparticles 
dispersed in water have a surface charge, caused by ionization or absorption of charged 
species. The charged particles are surrounded in solution by different ionic layers, whose 
composition is different from that of the bulk. When they move in solution (Brownian 
movement for example) the particles move together with a double ionic layer. The Zeta 
potential is the potential at the level of this double layer, also called the “slipping plane”. The 
zeta potential turns out to be the main force of the interactions between the particles, and it is 
very sensitive to the composition of the species loaded into the dispersion. For nanoparticles, 
particles that are small enough or of low density to remain suspended, the value of the Zeta 
Potential makes it possible to predict their stability. Indeed, a high zeta potential value (i.e. 
<30mV e> + 30mV) causes the nanoparticles to remain far from each other, repelling each 








b. A mathematical model perfectly predicts the effect of compressive stress on 
drug efficacy. 
We assume that the total number of cells N varies in the spheroid according to 
 
where Np, Nd, Na are the number of proliferating cells, cells dying due to drug action and 
apoptosis, respectively. We assume that these terms have the following functional form: 
 
where ρ is the cellular density, γ, δ, α, are the proliferation, drug-induced death and apoptosis 
rates, respectively, and ω is the radial distribution of proliferating cells in the spheroid (see the 
SI of [1]). In the following we assume that cell proliferation is exponentially distributed over 
the spheroid radius, with a characteristic length l: 
 




By calculating the integrals, we obtain 
 
We assume that the characteristic proliferation length is small if compared to the radius. 
Under this condition, the latter equation simplifies to 
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The variation of cell density ˙ρ is linked to the pressure that is exerted on the spheroid. When 
spheroids are compressed by Dextran, this term can be set to zero over the timescale of 
spheroid growth. In the case of compression by agarose, however, pressure changes over time 
need to be taken into account. This happens because the spheroid deforms the agarose while 
growing and the gel responds elastically by exerting a pressure on the spheroid. We assume 
that under the deformation regime that occurs in our experiments the agarose can be described 
by a linear elastic behavior. Therefore, the variation of density ˙ρ and pressure P˙ can be 
linked by the following relation 
   





where β = 1 + 4E/(9χ). Note that the proliferation rate and characteristic length γ and `, as well 
as the apoptotic rate α, depend on pressure and should be written as a function of spheroid 
radius. However, previous experimental work [1] as well as our observations (see Figure 1) 
suggest that the latter quantities reach an asymptotic value after a few kPa of pressure. Similar 
pressure values are obtained in the agarose gels that we consider even for small deformations, 
so that we can neglect the dependence of γ, ℓ and α on the spheroid radius and use directly 
their asymptotic values. 
Since our experiments are performed over a timescale in which apoptotic death in the 
spheroid is not thoroughly developed, i.e. αt/(3β) ≪ 1, we rewrite the growth equation as 
 
   
where g is the effective growth rate (including the early effects of cell apoptosis in the 
spheroid), and d is the death rate induced by the drug. In writing the last equation we assumed 
that d is independent of the external pressure acting on the spheroid. The dependence on 
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pressure is only considered for the growth rate g, which takes the value g0 in control 
conditions (i.e. no compression and no drug). 
 
Figure 4: Growth rates estimated from the Dextran experiments. 
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